<SEC-DOCUMENT>0001193125-23-264162.txt : 20231026
<SEC-HEADER>0001193125-23-264162.hdr.sgml : 20231026
<ACCEPTANCE-DATETIME>20231026170100
ACCESSION NUMBER:		0001193125-23-264162
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		18
CONFORMED PERIOD OF REPORT:	20231026
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20231026
DATE AS OF CHANGE:		20231026

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Monte Rosa Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001826457
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-40522
		FILM NUMBER:		231350898

	BUSINESS ADDRESS:	
		STREET 1:		321 HARRISON AVENUE
		STREET 2:		SUITE 900
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02118
		BUSINESS PHONE:		617-949-2643

	MAIL ADDRESS:	
		STREET 1:		321 HARRISON AVENUE
		STREET 2:		SUITE 900
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02118
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>d512767d8k.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8" ?>
<html xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:glue="http://monterosatx.com/20231026" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns="http://www.w3.org/1999/xhtml">
<head>
<title>8-K</title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
   <body><div style="display:none"> <ix:header> <ix:hidden> <ix:nonNumeric name="dei:AmendmentFlag" contextRef="duration_2023-10-26_to_2023-10-26">false</ix:nonNumeric> <ix:nonNumeric id="Hidden_dei_EntityCentralIndexKey" name="dei:EntityCentralIndexKey" contextRef="duration_2023-10-26_to_2023-10-26">0001826457</ix:nonNumeric> </ix:hidden> <ix:references> <link:schemaRef xlink:type="simple" xlink:href="glue-20231026.xsd" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase"></link:schemaRef> </ix:references> <ix:resources> <xbrli:context id="duration_2023-10-26_to_2023-10-26"> <xbrli:entity> <xbrli:identifier scheme="http://www.sec.gov/CIK">0001826457</xbrli:identifier> </xbrli:entity> <xbrli:period> <xbrli:startDate>2023-10-26</xbrli:startDate> <xbrli:endDate>2023-10-26</xbrli:endDate> </xbrli:period> </xbrli:context> </ix:resources> </ix:header> </div> <div style="text-align:center"> <div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto"> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p> <p style="margin-top:4pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">UNITED STATES</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">SECURITIES AND EXCHANGE COMMISSION</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Washington, D.C. 20549</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman;font-weight:bold;text-align:center">FORM <span style="white-space:nowrap"><ix:nonNumeric name="dei:DocumentType" contextRef="duration_2023-10-26_to_2023-10-26">8-K</ix:nonNumeric></span></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">CURRENT REPORT</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Pursuant to Section&#160;13 or 15(d)</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">of the Securities Exchange Act of 1934</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman;font-weight:bold;text-align:center">Date of Report (Date of earliest event reported): <ix:nonNumeric name="dei:DocumentPeriodEndDate" contextRef="duration_2023-10-26_to_2023-10-26" format="ixt:datemonthdayyearen">October 26, 2023</ix:nonNumeric></p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman;font-weight:bold;text-align:center"> <ix:nonNumeric name="dei:EntityRegistrantName" contextRef="duration_2023-10-26_to_2023-10-26">MONTE ROSA THERAPEUTICS, INC.</ix:nonNumeric> </p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Exact name of registrant as specified in its charter)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" contextRef="duration_2023-10-26_to_2023-10-26" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityFileNumber" contextRef="duration_2023-10-26_to_2023-10-26">001-40522</ix:nonNumeric></span></span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold"><span style="white-space:nowrap"><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="duration_2023-10-26_to_2023-10-26">84-3766197</ix:nonNumeric></span></span></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(State or other jurisdiction<br />of incorporation)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(Commission<br />File Number)</span></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><span style="font-weight:bold">(I.R.S. Employer<br />Identification No.)</span></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="duration_2023-10-26_to_2023-10-26">321 Harrison Avenue</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressAddressLine2" contextRef="duration_2023-10-26_to_2023-10-26">Suite 900</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="duration_2023-10-26_to_2023-10-26">Boston</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="duration_2023-10-26_to_2023-10-26">MA</ix:nonNumeric> <ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="duration_2023-10-26_to_2023-10-26">02118</ix:nonNumeric></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Address of principal executive offices, including zip code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center"><ix:nonNumeric name="dei:CityAreaCode" contextRef="duration_2023-10-26_to_2023-10-26">(617)</ix:nonNumeric> <span style="white-space:nowrap"><ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="duration_2023-10-26_to_2023-10-26">949-2643</ix:nonNumeric></span></p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Registrant&#8217;s telephone number, including area code)</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">Not Applicable</p> <p style="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">(Former Name or Former Address, if Changed Since Last Report)</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <div style="text-align:center"> <p style="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%;text-align:center;margin-left: auto;margin-right: auto">&#160;</p></div> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Check the appropriate box below if the Form <span style="white-space:nowrap">8-K</span> filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:WrittenCommunications" contextRef="duration_2023-10-26_to_2023-10-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:SolicitingMaterial" contextRef="duration_2023-10-26_to_2023-10-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left">Soliciting material pursuant to Rule <span style="white-space:nowrap">14a-12</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14a-12)</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementTenderOffer" contextRef="duration_2023-10-26_to_2023-10-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">14d-2(b)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.14d-2(b))</span></p></td></tr></table> <p style="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="border-collapse:collapse; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:4%;vertical-align:top"><ix:nonNumeric name="dei:PreCommencementIssuerTenderOffer" contextRef="duration_2023-10-26_to_2023-10-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></td>
<td style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;text-align:left"><span style="white-space:nowrap">Pre-commencement</span> communications pursuant to Rule <span style="white-space:nowrap">13e-4(c)</span> under the Exchange Act (17 CFR <span style="white-space:nowrap">240.13e-4(c))</span></p></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Securities registered pursuant to Section&#160;12(b) of the Act:</p> <p style="font-size:8pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="border-collapse:collapse; font-family:Times New Roman; font-size:8pt;width:100%;border:0;margin:0 auto">
<tr>
<td style="width:34%"></td>
<td style="vertical-align:bottom"></td>
<td style="width:32%"></td>
<td style="vertical-align:bottom;width:1%"></td>
<td style="width:32%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom;white-space:nowrap"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Title of each class</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Trading<br />Symbol(s)</p></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; border-bottom:1.00pt solid #000000;vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Name of each exchange<br />on which registered</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:Security12bTitle" contextRef="duration_2023-10-26_to_2023-10-26">Common Stock, $0.0001 par value per share</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:TradingSymbol" contextRef="duration_2023-10-26_to_2023-10-26">GLUE</ix:nonNumeric></td>
<td style="vertical-align:bottom">&#160;</td>
<td style=" text-align: center;margin:auto; vertical-align:top"><ix:nonNumeric name="dei:SecurityExchangeName" contextRef="duration_2023-10-26_to_2023-10-26" format="ixt-sec:exchnameen">The Nasdaq Global Select Market</ix:nonNumeric></td></tr></table> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167; 230.405 of this chapter) or Rule <span style="white-space:nowrap">12b-2</span> of the Securities Exchange Act of 1934 (&#167; <span style="white-space:nowrap">240.12b-2</span> of this chapter).</p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Emerging growth company&#8194;<ix:nonNumeric name="dei:EntityEmergingGrowthCompany" contextRef="duration_2023-10-26_to_2023-10-26" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></p> <p style="margin-top:8pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a) of the Exchange Act.&#8194;<ix:nonNumeric name="dei:EntityExTransitionPeriod" contextRef="duration_2023-10-26_to_2023-10-26" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></p> <p style="font-size:10pt;margin-top:0pt;margin-bottom:0pt">&#160;</p> <p style="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&#160;</p> <p style="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&#160;</p></div></div>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">

<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;1.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Entry into a Material Definitive Agreement. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;26, 2023, Monte Rosa Therapeutics, Inc. (the &#8220;Company&#8221;) entered into a securities purchase agreement (the &#8220;Purchase Agreement&#8221;) with certain institutional investors relating to the issuance and sale of <span style="white-space:nowrap">pre-funded</span> warrants to purchase 10,000,400 shares of the Company&#8217;s common stock (the <span style="white-space:nowrap">&#8220;Pre-Funded</span> Warrants&#8221;) to such investors (the &#8220;Offering&#8221;). The <span style="white-space:nowrap">Pre-Funded</span> Warrants will be sold to the investors at an offering price of $2.4999 per share under such <span style="white-space:nowrap">Pre-Funded</span> Warrant, which represents the per share offering price for the Company&#8217;s common stock less a $0.0001 per share exercise price for each such <span style="white-space:nowrap">Pre-Funded</span> Warrant. The Purchase Agreement contains customary representations and warranties, conditions to closing, termination provisions and indemnification obligations, including for liabilities under the Securities Act of 1933, as amended. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The <span style="white-space:nowrap">Pre-Funded</span> Warrants are exercisable at any time after the date of issuance. A holder of a <span style="white-space:nowrap">Pre-Funded</span> Warrant may not exercise such <span style="white-space:nowrap">Pre-Funded</span> Warrant if the holder, together with its affiliates, would beneficially own more than 4.99% (or, at the election of the holder, up to 19.99%) of the number of shares of the Company&#8217;s common stock outstanding immediately after giving effect to such exercise. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The gross proceeds from the Offering will be approximately $25.0&#160;million, before paying estimated offering expenses. Delivery of the <span style="white-space:nowrap">Pre-Funded</span> Warrants is expected to take place on or about October&#160;30, 2023, subject to customary closing conditions. The Offering is being made pursuant to the shelf registration statement on Form <span style="white-space:nowrap">S-3</span> (File <span style="white-space:nowrap">No.&#160;333-266003)</span> previously filed by the Company with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on July&#160;1, 2022 and declared effective by the SEC on July&#160;13, 2022. </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The form of <span style="white-space:nowrap">Pre-Funded</span> Warrant and the Purchase Agreement are filed as Exhibit 4.1 and Exhibit 10.1, respectively, to this Current Report on Form <span style="white-space:nowrap">8-K.</span> The foregoing description of the respective terms of the <span style="white-space:nowrap">Pre-Funded</span> Warrants and the Purchase Agreement is not intended to be complete and is qualified in its entirety by reference to such Exhibits. A copy of the opinion of Goodwin Procter LLP relating to the legality of the issuance and sale of the <span style="white-space:nowrap">Pre-Funded</span> Warrants in the Offering is filed as Exhibit 5.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;8.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Other Events. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On October&#160;26, 2023, the Company issued a press release entitled &#8220;Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering Priced <span style="white-space:nowrap"><span style="white-space:nowrap">At-the-Market</span></span> Under Nasdaq Rules.&#8221; A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form <span style="white-space:nowrap">8-K.</span> </p> <p style="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;border:0;width:100%" cellpadding="0" cellspacing="0">
<tr style="page-break-inside:avoid">
<td style="width:11%;vertical-align:top" align="left"><span style="font-weight:bold">Item&#8201;9.01</span></td>
<td align="left" style="vertical-align:top"> <p style=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:left">Financial Statements and Exhibits. </p></td></tr></table> <p style="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold">(d) Exhibits. </p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0;margin:0 auto">


<tr>

<td></td>

<td style="vertical-align:bottom;width:4%"></td>
<td style="width:93%"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<td style="vertical-align:bottom;white-space:nowrap" align="center"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:inline-block; font-size:8pt; font-family:Times New Roman;font-weight:bold;text-align:center">Exhibit<br />No.</p></td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:bottom;white-space:nowrap"> <p style=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:Times New Roman;font-weight:bold">Description</p></td></tr>


<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;4.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d512767dex41.htm">Form of <span style="white-space:nowrap">Pre-Funded</span> Warrant </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">&#8194;5.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d512767dex51.htm">Opinion of Goodwin Procter LLP </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">10.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d512767dex101.htm">Securities Purchase Agreement, dated October&#160;26, 2023 </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">23.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d512767dex51.htm">Consent of Goodwin Procter LLP (included in Exhibit 5.1) </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">99.1</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top"><a href="d512767dex991.htm">Press Release dated October&#160;26, 2023, entitled &#8220;Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering Priced <span style="white-space:nowrap"><span style="white-space:nowrap">At-the-Market</span></span> Under Nasdaq Rules.&#8221; </a></td></tr>
<tr style="font-size:1pt">
<td style="height:6pt"></td>
<td style="height:6pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:top;white-space:nowrap">104</td>
<td style="vertical-align:bottom">&#160;&#160;</td>
<td style="vertical-align:top">Cover Page Interactive Data File (embedded within the Inline XBRL document)</td></tr>
</table> <p style="font-size:24pt; margin-top:0pt; margin-bottom:0pt">&#160;</p>
</div></div>



<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<hr style="color:#999999;height:3px;width:100%" />

<div style="text-align:center"><div style="width:8.5in;text-align:left;margin-left: auto;margin-right: auto">
 <p style="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman;font-weight:bold;text-align:center">SIGNATURE </p> <p style="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p> <p style="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&#160;</p>
<table cellspacing="0" cellpadding="0" style="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt;width:100%;border:0">


<tr>

<td style="width:45%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:4%"></td>

<td style="vertical-align:bottom"></td>
<td style="width:3%"></td>

<td style="vertical-align:bottom;width:1%"></td>
<td style="width:45%"></td></tr>


<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom" colspan="3">Monte Rosa Therapeutics, Inc.</td></tr>
<tr style="font-size:1pt">
<td style="height:12pt"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td>
<td style="height:12pt" colspan="2"></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom">Date: October&#160;26, 2023</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:top">By:</td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"> <p style="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Markus Warmuth</p></td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">Markus Warmuth</td></tr>
<tr style="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom"></td>
<td style="vertical-align:bottom">&#160;</td>
<td style="vertical-align:bottom">President and Chief Executive Officer</td></tr>
</table>
</div></div>

</body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>d512767dex41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-4.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 4.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF <FONT STYLE="white-space:nowrap">PRE-FUNDED</FONT> WARRANT TO PURCHASE COMMON STOCK </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>MONTE ROSA THERAPEUTICS, INC. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="51%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Number of Shares: [&#8195;&#8195;&#8195;&#8195;]</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">(subject to adjustment)&#8195;&#8195;&#8195;&#8195;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Warrant No. <U><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">2023-PF-0[&#8195;]</FONT></FONT></U></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="right">Original&nbsp;Issue&nbsp;Date:&nbsp;October [&#8195;], 2023</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monte Rosa Therapeutics, Inc., a Delaware corporation (the &#147;<B>Company</B>&#148;), hereby certifies that, for good and
valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [&#8195;&#8195;&#8195;&#8195;] or its registered assigns (the &#147;<B>Holder</B>&#148;), is entitled, subject to the terms set forth below, to purchase from the
Company up to a total of [&#8195;] shares of common stock, $0.0001 par value per share (the &#147;<B>Common Stock</B>&#148;), of the Company (each such share, a &#147;<B>Warrant Share</B>&#148; and all such shares, the &#147;<B>Warrant
Shares</B>&#148;) at an exercise price equal to $0.0001 per share (as adjusted from time to time as provided in <U>Section</U><U></U><U>&nbsp;9</U> herein, the &#147;<B>Exercise Price</B>&#148;), upon surrender of this Warrant to Purchase Common
Stock (including any Warrants to Purchase Common Stock issued in exchange, transfer or replacement hereof, the &#147;<B>Warrant</B>&#148;) at any time and from time to time on or after the date hereof (the &#147;<B>Original Issue Date</B>&#148;),
subject to the following terms and conditions: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">1. <I>Definitions</I>. For purposes of this Warrant, the following terms shall have the following meanings:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) &#147;<B>Affiliate</B>&#148; means any Person directly or indirectly controlled by, controlling or under common control with, a
Holder, but only for so long as such control shall continue. For purposes of this definition, &#147;control&#148; (including, with correlative meanings, &#147;controlled by&#148;, &#147;controlling&#148; and &#147;under common control with&#148;)
means, with respect to a Person, possession, direct or indirect, of (a)&nbsp;the power to direct or cause direction of the management and policies of such Person (whether through ownership of securities or partnership or other ownership interests,
by contract or otherwise), or (b)&nbsp;at least 50% of the voting securities (whether directly or pursuant to any option, warrant or other similar arrangement) or other comparable equity interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) &#147;<B>Attribution Parties</B>&#148; means, collectively, the following Persons and entities: (i)&nbsp;any direct or indirect Affiliates
of the Holder, (ii)&nbsp;any Person acting or who could be deemed to be acting as a Section&nbsp;13(d) &#147;group&#148; together with the Holder or any Attribution Parties and (iii)&nbsp;any other Persons whose beneficial ownership of the
Company&#146;s Common Stock would or could be aggregated with the Holder&#146;s and/or any other Attribution Parties for purposes of Section&nbsp;13(d) or Section&nbsp;16 of the Exchange Act. For clarity, the purpose of the foregoing is to subject
collectively the Holder and all other Attribution Parties to the Maximum Percentage. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) &#147;<B>Closing Sale Price</B>&#148; means, for
any security as of any date, the last trade price for such security on the Principal Trading Market for such security, as reported by Bloomberg Financial Markets, or, if such Principal Trading Market begins to operate on an extended hours basis and
does not designate the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg Financial Markets, or if the foregoing do not apply, the last trade price of such security in the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market on the electronic bulletin board for such security as reported by Bloomberg Financial Markets. If the Closing Sale Price cannot be calculated for a
security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to agree
upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment to determine the fair market value. The Board of Directors&#146; determination shall be binding upon all parties absent
demonstrable error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other similar transaction during the applicable calculation period. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) &#147;<B>Commission</B>&#148; means the United States Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) &#147;<B>Exchange Act</B>&#148; means the Securities Exchange Act of 1934, as amended. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Group</B>&#148; shall have the meaning ascribed to it in Section&nbsp;13(d) of
the Exchange Act, and all related rules, regulations and jurisprudence. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) &#147;<B>Person</B>&#148; means an individual, a limited
liability company, a partnership, a joint venture, a corporation, a trust, an unincorporated organization, any other entity and a government or any department or agency thereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) &#147;<B>Principal Trading Market</B>&#148; means the national securities exchange or other trading market on which the Common Stock is
primarily listed on and quoted for trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h)
&#147;<B>Purchase Agreement</B>&#148; means that certain Securities Purchase Agreement dated as of October&nbsp;26, 2023, by and among the Company and each of the investors party thereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(i) &#147;<B>Registration Statement</B>&#148; means the Company&#146;s Registration Statement on Form
<FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-266003),</FONT> that became effective on July&nbsp;13, 2022. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(j) &#147;<B>Securities Act</B>&#148; means the Securities Act of 1933, as amended. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(k) &#147;<B>Standard Settlement Period</B>&#148; means the standard settlement period, expressed in a number of Trading Days, for the
Principal Trading Market with respect to the Common Stock that is in effect on the date of delivery of an applicable Exercise Notice, which as of the Original Issuance Date was &#147;T+2.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(l) &#147;<B>Trading Day</B>&#148; means any weekday on which the Principal Trading Market is normally open for trading. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(m) &#147;<B>Transfer Agent</B>&#148; means Computershare Trust Company, N.A., the Company&#146;s transfer agent and registrar for the Common
Stock, and any successor appointed in such capacity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">2. <I>Issuance of Securities; Registration of Warrants</I>. The Warrant, as initially issued by the
Company, is offered and sold pursuant to the Registration Statement. As of the Original Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant to the Registration
Statement or an exchange meeting the requirements of Section&nbsp;3(a)(9) of the Exchange Act as in effect on the Original Issue Date, the Warrant Shares, are not &#147;restricted securities&#148; under Rule 144 promulgated under the Securities Act.
The Company shall register ownership of this Warrant, upon records to be maintained by the Company for that purpose (the &#147;<B>Warrant Register</B>&#148;), in the name of the record Holder (which shall include the initial Holder or, as the case
may be, any assignee to which this Warrant is permissibly assigned hereunder) from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose of any exercise hereof or any
distribution to the Holder, and for all other purposes, absent actual notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">3. <I>Registration of Transfers</I>. Subject to compliance
with all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion of this Warrant in the Warrant Register, upon surrender of this Warrant, and payment for all applicable transfer
taxes (if any). Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such new warrant, a &#147;<B>New Warrant</B>&#148;) evidencing the portion of this Warrant so transferred
shall be issued to the transferee, and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed
the acceptance by such transferee of all of the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or will cause its Transfer Agent to, prepare, issue and deliver at the
Company&#146;s own expense any New Warrant under this <U>Section</U><U></U><U>&nbsp;3</U>. Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder for all purposes, and the
Company shall not be affected by any notice to the contrary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">4. <I>Exercise of Warrants</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) All or any part of this Warrant shall be exercisable by the registered Holder in any manner permitted by this Warrant (including
Section&nbsp;11) at any time and from time to time on or after the Original Issue Date, and such rights shall not expire. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) The Holder
may exercise this Warrant by delivering to the Company (i)&nbsp;an exercise notice, in the form attached as <U>Schedule 1</U> hereto (the &#147;<B>Exercise Notice</B>&#148;), completed and duly signed, and (ii)&nbsp;payment of the Exercise Price for
the number of Warrant Shares as to which this Warrant is being exercised (which may take the form of a &#147;cashless exercise&#148; if so indicated in the Exercise Notice pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below), and the date on
which the last of such items is delivered to the Company (as determined in accordance with the notice provisions hereof) is an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
<B>&#147;Exercise Date</B>.&#148; The Holder shall not be required to deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall
have the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining number of Warrant Shares, if any. <B></B> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">5. <I>Delivery of Warrant Shares</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Upon
exercise of this Warrant, the Company shall promptly (but in no event later than the number of Trading Days comprising the Standard Settlement Period following the Exercise Date), upon the request of the Holder, credit such aggregate number of
shares of Common Stock specified by the Holder in the Exercise Notice and to which the Holder is entitled pursuant to such exercise (the &#147;<B>Exercise Shares</B>&#148;) to the Holder&#146;s or its designee&#146;s balance account with The
Depository Trust Company (&#147;<B>DTC</B>&#148;) through its Deposit Withdrawal At Custodian system, or if the Transfer Agent is then a participant in the DTC Fast Automated Securities Transfer Program (the &#147;<B>FAST Program</B>&#148;) and
either (A)&nbsp;there is an effective registration statement permitting the issuance of the Warrant Shares to or the resale of such Warrant Shares by the Holder or (B)&nbsp;the Exercise Shares are eligible for resale by the Holder without volume or <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> restrictions pursuant to Rule 144 promulgated under the Securities Act (assuming cashless exercise of this Warrant). If the Transfer Agent is not a member of
the FAST Program or if (A)&nbsp;and (B) above are not true, the Transfer Agent will either (i)&nbsp;record the Exercise Shares in the name of the Holder or its designee on the certificates reflecting the Exercise Shares with an appropriate legend
regarding restriction on transferability, which shall be issued and dispatched by overnight courier to the address as specified in the Exercise Notice, and on the Company&#146;s share register or (ii)&nbsp;issue such Exercise Shares in the name of
the Holder or its designee in restricted book-entry form in the Company&#146;s share register. The Holder, or any natural person or legal entity (each, a &#147;<B>Person</B>&#148;) so designated by the Holder to receive Warrant Shares, shall be
deemed to have become the holder of record of such Warrant Shares as of the Exercise Date, irrespective of the date such Warrant Shares are credited to the Holder&#146;s DTC account, the date of the book entry positions or the date of delivery of
the certificates evidencing such Exercise Shares, as the case may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) If the Company fails to deliver to the Holder or its designee
Exercise Shares in the manner required pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> within the Standard Settlement Period following the Exercise Date and the Holder purchases (in an open market transaction or otherwise) shares of Common Stock
to deliver in satisfaction of a sale by the Holder of the Warrant Shares which the Holder anticipated receiving upon such exercise (a &#147;<B><FONT STYLE="white-space:nowrap">Buy-In</FONT></B>&#148;) but did not receive within the Standard
Settlement Period, then the Company shall, within two (2)&nbsp;Trading Days after the Holder&#146;s request and in the Holder&#146;s sole discretion, either (1)&nbsp;pay in cash to the Holder an amount equal to the Holder&#146;s total purchase price
(including brokerage commissions, if any) for the shares of Common Stock so purchased, at which point the Company&#146;s obligation to issue and deliver such Exercise Shares shall terminate or (2)&nbsp;promptly honor its obligation to deliver to the
Holder or its designee the Exercise Shares pursuant to <U>Section</U><U></U><U>&nbsp;5(a)</U> and pay cash to the Holder in an amount equal to the excess (if any) of Holder&#146;s total purchase price (including brokerage commissions, if any) for
the shares of Common Stock so purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> less the product of (A)&nbsp;the number of shares of Common Stock purchased in the <FONT STYLE="white-space:nowrap">Buy-In,</FONT> times (B)&nbsp;the
Closing Sale Price of a share of Common Stock on the Exercise Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) To the extent permitted by law and subject to
<U>Section</U><U>&nbsp;5(b)</U>, the Company&#146;s obligations to issue and deliver Warrant Shares in accordance with and subject to the terms hereof (including the limitations set forth in <U>Section</U><U></U><U>&nbsp;11</U> below) are absolute
and unconditional, irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof, the recovery of any judgment against any Person or any action to enforce the same, or any
setoff, counterclaim, recoupment, limitation or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation or alleged violation of law by the Holder or any other Person, and
irrespective of any other circumstance that might otherwise limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Subject to <U>Section</U><U>&nbsp;5(b)</U>, nothing herein shall limit the
Holder&#146;s right to pursue any other remedies available to it hereunder, at law or in equity including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company&#146;s failure to timely deliver
shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">6. <I>Charges, Taxes and Expenses</I>. Issuance and
delivery of shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of
the issuance of such certificates, all of which taxes and expenses shall be paid by the Company; <I>provided</I>, <I>however</I>, that the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the
registration of any Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or
receiving Warrant Shares upon exercise hereof. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">7. <I>Replacement of Warrant</I>. If this Warrant is mutilated, lost, stolen or destroyed, the Company shall
issue or cause to be issued in exchange and substitution for and upon cancellation hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory to the Company of such loss, theft
or destruction (in such case) and, in each case, a customary and reasonable contractual indemnity, if requested by the Company. If a New Warrant is requested as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated
Warrant to the Company as a condition precedent to the Company&#146;s obligation to issue the New Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">8. <I>Reservation of Warrant Shares</I>. The
Company covenants that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue
Warrant Shares upon exercise of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise of this entire Warrant, free from preemptive rights or any other contingent purchase rights
of persons other than the Holder (taking into account the adjustments and restrictions of <U>Section</U><U></U><U>&nbsp;9</U>). The Company covenants that all Warrant Shares so issuable and deliverable shall, upon issuance and the payment of the
applicable Exercise Price in accordance with the terms hereof, be duly and validly authorized, issued and fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> The Company will take all such action as may be reasonably necessary to
assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation, or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be
listed. The Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par value of the Common Stock at any time while this Warrant is outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">9. <I>Certain Adjustments</I>. The Exercise Price and number of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to
time as set forth in this <U>Section</U><U></U><U>&nbsp;9</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>Stock Dividends and Splits</U>. If the Company, at any time while
this Warrant is outstanding, (i)&nbsp;pays a stock dividend on its Common Stock or otherwise makes a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms of such stock on the
Original Issue Date or as amended, that is payable in shares of Common Stock, (ii)&nbsp;subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii)&nbsp;combines its outstanding shares of Common Stock into
a smaller number of shares of Common Stock or (iv)&nbsp;issues by reclassification of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Exercise Price shall be multiplied by a fraction, the
numerator of which shall be the number of shares of Common Stock outstanding immediately before such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event. Any adjustment made
pursuant to clause (i)&nbsp;of this paragraph shall become effective immediately after the record date for the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date shall have
been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to this
paragraph as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii), (iii) or (iv)&nbsp;of this paragraph shall become effective immediately after the effective date of such subdivision, combination or issuance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Pro Rata Distributions</U>. If, on or after the Original Issue Date, the Company shall declare or make any dividend or other pro rata
distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock, by way of return of capital or otherwise (including, without limitation, any distribution of cash, stock or other securities, property, options,
evidence of indebtedness or any other assets by way of a dividend, spin off, reclassification, corporate rearrangement, scheme of arrangement or other similar transaction, but, for the avoidance of doubt, excluding any distribution of shares of
Common Stock subject to <U>Section</U><U></U><U>&nbsp;9(a)</U>, any distribution of Purchase Rights (as defined below) subject to <U>Section</U><U></U><U>&nbsp;9(c)</U> and any Fundamental Transaction (as defined below) subject to
<U>Section</U><U></U><U>&nbsp;9(d))</U> (a &#147;<B>Distribution</B>&#148;) then, in each such case, the Holder shall be entitled to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage (as defined below))
immediately before the date on which a record is taken for such Distribution, or, if no such record is taken, the date </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
as of which the record holders of shares of Common Stock are to be determined for the participation in such Distribution (provided, that to the extent that the Holder&#146;s right to participate
in any such Distribution would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled to participate in such Distribution to such extent (and shall not be entitled to beneficial
ownership of such shares of Common Stock as a result of such Distribution (and beneficial ownership) to such extent) and the portion of such Distribution shall be held in abeyance for the benefit of the Holder until such time or times as its right
thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted such Distribution (and any Distributions declared or made on such initial Distribution or
on any subsequent Distribution held similarly in abeyance) to the same extent as if there had been no such limitation). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Purchase
Rights</U>. If at any time on or after the Original Issue Date, the Company grants, issues or sells any Options, Convertible Securities or rights to purchase stock, warrants, securities or other property, in each case pro rata to the record holders
of any class of Common Stock (the &#147;<B>Purchase Rights</B>&#148;), then the Holder will be entitled to acquire, upon the terms applicable to such Purchase Rights, the aggregate Purchase Rights which the Holder could have acquired if the Holder
had held the number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations or restrictions on exercise of this Warrant, including without limitation, the Maximum Percentage) immediately before
the date on which a record is taken for the grant, issuance or sale of such Purchase Rights, or, if no such record is taken, the date as of which the record holders of Common Stock are to be determined for the grant, issuance or sale of such
Purchase Rights (provided, that to the extent that the Holder&#146;s right to participate in any such Purchase Right would result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, then the Holder shall not be entitled
to participate in such Purchase Right to such extent (and shall not be entitled to beneficial ownership of such Common Stock as a result of such Purchase Right (and beneficial ownership) to such extent) and such Purchase Right to such extent shall
be held in abeyance for the benefit of the Holder until such time or times as its right thereto would not result in the Holder and the other Attribution Parties exceeding the Maximum Percentage, at which time or times the Holder shall be granted
such right (and any Purchase Right granted, issued or sold on such initial Purchase Right or on any subsequent Purchase Right to be held similarly in abeyance) to the same extent as if there had been no such limitation). As used in this
Section&nbsp;9(c), (i) &#147;Options&#148; means any rights, warrants or options to subscribe for or purchase shares of Common Stock or Convertible Securities and (ii) &#147;Convertible Securities&#148; mean any stock or securities (other than
Options) directly or indirectly convertible into or exercisable or exchangeable for shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Fundamental
Transactions</U>. If, at any time while this Warrant is outstanding (i)&nbsp;the Company effects any merger or consolidation of the Company with or into another Person, in which the Company is not the surviving entity or in which the stockholders of
the Company immediately prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity immediately after such merger or consolidation, (ii)&nbsp;the Company effects any sale to
another Person of all or substantially all of its assets in one or a series of related transactions, (iii)&nbsp;pursuant to any tender offer or exchange offer (whether by the Company or another Person), holders of capital stock tender shares
representing more than 50% of the voting power of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv)&nbsp;the Company consummates a stock purchase agreement or other business
combination (including, without limitation, a reorganization, recapitalization, <FONT STYLE="white-space:nowrap">spin-off</FONT> or scheme of arrangement) with another Person whereby such other Person acquires more than 50% of the voting power of
the capital stock of the Company (except for any such transaction in which the stockholders of the Company immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately after the
transaction) or (v)&nbsp;the Company effects any reclassification of the Common Stock or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than
as a result of a subdivision or combination of shares of Common Stock covered by <U>Section</U><U></U><U>&nbsp;9(a)</U> above) (in any such case, a &#147;<B>Fundamental Transaction</B>&#148;), then following such Fundamental Transaction the Holder
shall have the right to receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior
to such Fundamental Transaction, the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations on exercise contained herein (the &#147;<B>Alternate Consideration</B>&#148;). The
Company shall not effect any Fundamental Transaction in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i)&nbsp;the Alternate Consideration is solely cash and the Company
provides for the simultaneous &#147;cashless exercise&#148; of this Warrant pursuant to <U>Section</U><U></U><U>&nbsp;10</U> below or (ii)&nbsp;prior to or simultaneously with the consummation thereof, any successor to the Company, surviving entity
or other Person (including any purchaser of assets of the Company) shall assume the obligation to deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled to receive, and the
other obligations under this Warrant. The provisions of this paragraph (c)&nbsp;shall similarly apply to subsequent transactions analogous of a Fundamental Transaction type. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Number of Warrant Shares</U>. Simultaneously with any adjustment to the Exercise
Price pursuant to <U>Section</U><U></U><U>&nbsp;9</U>, the number of Warrant Shares that may be purchased upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise Price
payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price in effect immediately prior to such adjustment. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Calculations</U>. All calculations under this <U>Section</U><U></U><U>&nbsp;9</U> shall be made to the nearest <FONT
STYLE="white-space:nowrap">one-tenth</FONT> of one cent or the nearest share, as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Notice of Adjustments</U>. Upon the
occurrence of each adjustment pursuant to this <U>Section</U><U></U><U>&nbsp;9</U>, the Company at its expense will, at the written request of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant
and prepare a certificate setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares or other securities issuable upon exercise of this Warrant (as applicable), describing the
transactions giving rise to such adjustments and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a copy of each such certificate to the Holder and to the Transfer Agent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Notice of Corporate Events</U>. If, while this Warrant is outstanding, the Company (i)&nbsp;declares a dividend or any other
distribution of cash, securities or other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for or purchase any capital stock of the Company or any subsidiary,
(ii)&nbsp;authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental Transaction or (iii)&nbsp;authorizes the voluntary dissolution, liquidation or winding up of the affairs of the Company,
then, except if such notice and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such transaction at least ten
(10)&nbsp;days prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or vote with respect to such transaction; provided, however, that the failure to deliver such notice or any
defect therein shall not affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding, the Company authorizes or approves, enters into any agreement contemplating or solicits
stockholder approval for any Fundamental Transaction contemplated by <U>Section</U><U></U><U>&nbsp;9(c)</U>, other than a Fundamental Transaction under clause (iii)&nbsp;of <U>Section</U>&nbsp;9(c), then, except if such notice and the contents
thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall deliver to the Holder a notice of such Fundamental Transaction at least thirty (30)&nbsp;days prior to the date such
Fundamental Transaction is consummated. In the event any notice contemplated by this Section&nbsp;9(g) and the contents thereof shall be deemed to constitute material <FONT STYLE="white-space:nowrap">non-public</FONT> information, the Company shall
(on the same time frame set forth in the applicable sentence above) offer the Holder the ability to sign a confidentiality agreement related thereto sufficient to allow the Holder to receive such notice (which offer shall not impart material <FONT
STYLE="white-space:nowrap">non-public</FONT> information to the Holder and which offer the Holder may, in its sole discretion, determine whether to accept or refuse to accept), and the Company shall deliver such notice immediately upon execution of
such confidentiality agreement. Holder agrees to maintain any information disclosed pursuant to this Section&nbsp;9(g) in confidence until such information is publicly available, and shall comply with applicable law with respect to trading in the
Company&#146;s securities following receipt of any such information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">10. <I>Payment of Exercise Price</I>. Notwithstanding anything contained herein to
the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price through a &#147;cashless exercise&#148;, in which event the Company shall issue to the Holder the number of Warrant Shares in an exchange of
securities effected pursuant to Section&nbsp;3(a)(9) of the Securities Act, as determined as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">X = Y
<FONT STYLE="white-space:nowrap">[(A-B)/A]</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">where: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;X&#148; equals the number of Warrant Shares to be issued to the Holder; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Y&#148; equals the total number of Warrant Shares with respect to which this Warrant is then being exercised; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;A&#148; equals the Closing Sale Price of the shares of Common Stock (as reported by Bloomberg Financial Markets) as of the Trading Day
on the date immediately preceding the Exercise Date; and </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;B&#148; equals the Exercise Price then in effect for the applicable Warrant Shares at
the time of such exercise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For purposes of Rule 144 promulgated under the Securities Act, it is intended, understood and acknowledged that the Warrant
Shares issued in a &#147;cashless exercise&#148; transaction shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced, on the date this Warrant was originally issued
(provided that the Commission continues to take the position that such treatment is proper at the time of such exercise). In the event that a registration statement registering the issuance of Warrant Shares is, for any reason, not effective at the
time of exercise of this Warrant, then the Warrant may only be exercised through a cashless exercise, as set forth in this <U>Section</U><U>&nbsp;10</U>. If the Warrant Shares are issued in such a cashless exercise, the Company acknowledges and
agrees that, in accordance with Section&nbsp;3(a)(9) of the Securities Act, the Exercise Shares issued in such exercise shall take on the registered characteristics of the Warrants being exercised and may be tacked on to the holding period of the
Warrants being exercised. Except as set forth in Section&nbsp;5(b) <FONT STYLE="white-space:nowrap">(Buy-In</FONT> remedy) and Section&nbsp;12 (payment of cash in lieu of fractional shares), in no event will the exercise of this Warrant be settled
in cash. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">11. <I>Limitations on Exercise</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) Notwithstanding anything to the contrary contained herein, the Company shall not effect the exercise of any portion of this Warrant, and
the Holder of the Warrant shall not have the right to exercise any portion of the Warrant, and any such exercise shall be null and void ab initio and treated as if the exercise had not been made, to the extent that immediately prior to or following
such exercise, the Holder, together with the Attribution Parties, beneficially owns or would beneficially own as determined in accordance with Section&nbsp;13(d) of the s Exchange Act and the rules promulgated thereunder, in excess of <B>4.99%</B>
(the &#147;<B>Maximum Percentage</B>&#148;) of the Common Stock that would be issued and outstanding following such exercise. For purposes of calculating beneficial ownership for determining whether the Maximum Percentage is or will be exceeded, the
aggregate number of shares of Common Stock held and/or beneficially owned by the Holder together with the Attribution Parties, shall include the number of shares of Common Stock held and/or beneficially owned by the Holder together with the
Attribution Parties plus the number of shares of Common Stock issuable upon exercise of the relevant Warrant with respect to which the determination is being made but shall exclude the number of shares of Common Stock which would be issuable upon
(i)&nbsp;exercise of the remaining, unexercised Warrant held and/or beneficially owned by the Holder or the Attribution Parties and (ii)&nbsp;exercise or conversion of the unexercised or unconverted portion of any other securities of the Company
held and/or beneficially owned by such Holder or any Attribution Party (including, without limitation, any convertible notes, convertible stock or warrants) that are subject to a limitation on conversion or exercise analogous to the limitation
contained herein. For purposes of this Paragraph 11(a), beneficial ownership of the Holder or the Attribution Parties shall, except as set forth in the immediately preceding sentence, be calculated and determined in accordance with
Section&nbsp;13(d) of the Exchange Act and the rules promulgated thereunder. For purposes of the Warrant, in determining the number of outstanding shares of Common Stock, a Holder of the Warrant may rely on the number of outstanding shares of Common
Stock as reflected in (1)&nbsp;the Company&#146;s most recent Form <FONT STYLE="white-space:nowrap">10-K,</FONT> Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> Current Report on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or other public
filing with the Securities and Exchange Commission, as the case may be, (2)&nbsp;a more recent public announcement by the Company or (3)&nbsp;any other notice by the Company or the Transfer Agent setting forth the number of shares of Common Stock
outstanding (such issued and outstanding shares, the &#147;<B>Reported Outstanding Share Number</B>&#148;). For any reason at any time, upon the written or oral request of the Holder, the Company shall within one (1)&nbsp;Business Day confirm orally
and in writing or by electronic mail to the Holder the number of shares of Common Stock then outstanding. The Holder shall disclose to the Company the number of shares of Common Stock that it, together with the Attribution Parties holds and/or
beneficially owns and has the right to acquire through the exercise of derivative securities and any limitations on exercise or conversion analogous to the limitation contained herein contemporaneously or immediately prior to submitting an Exercise
Notice for the relevant Warrant. If the Company receives an Exercise Notice from the Holder at a time when the actual number of outstanding shares of Common Stock is less than the Reported Outstanding Share Number, the Company shall (i)&nbsp;notify
the Holder in writing of the number of shares of Common Stock then outstanding and, to the extent that such Exercise Notice would otherwise cause the Holder&#146;s, together with the Attribution Parties&#146;, beneficial ownership, as determined
pursuant to this Section&nbsp;11(a), to exceed the Maximum Percentage, the Holder must notify the Company of a reduced number of Warrant Shares to be purchased pursuant to such Exercise Notice (the number of shares by which such purchase is reduced,
the &#147;Reduction Shares&#148;) and (ii)&nbsp;as soon as reasonably practicable, the Company shall return to the Holder any exercise price paid by the Holder for the Reduction Shares. In any case, the number of outstanding shares of Common Stock
shall be determined after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the Holder and the Attribution Parties since the date as of which the Reported Outstanding Share Number was reported. In the event that the issuance of Common Stock to the Holder upon exercise of
this Warrant results in the Holder, together with the Attribution Parties, being deemed to beneficially own, in the aggregate, more than the Maximum Percentage of the number of outstanding shares of Common Stock (as determined under
Section&nbsp;13(d) of the Exchange Act), the number of shares so issued by which the Holder&#146;s, together with the Attribution Parties&#146;, aggregate beneficial ownership exceeds the Maximum Percentage (the &#147;Excess Shares&#148;) shall be
deemed null and void and shall be cancelled ab initio, and the Holder and/or the Attribution Parties shall not have the power to vote or to transfer the Excess Shares. As soon as reasonably practicable after the issuance of the Excess Shares has
been deemed null and void, the Company shall return to the Holder the exercise price paid by the Holder for the Excess Shares. By written notice to the Company, a Holder of the Warrant may from time to time increase or decrease the Maximum
Percentage to any other percentage not in excess of 19.99% specified in such notice; provided that any increase in the Maximum Percentage will not be effective until the sixty-first (61st) day after such notice is delivered to the Company and shall
not negatively affect any partial exercise effected prior to such change. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) This <U>Section</U><U></U><U>&nbsp;11</U> shall not
restrict the number of shares of Common Stock which a Holder or the Attribution Parties may receive or beneficially own in order to determine the amount of securities or other consideration that such Holder or the Attribution Parties may receive in
the event of a Fundamental Transaction as contemplated in <U>Section</U><U></U><U>&nbsp;9(c)</U> of this Warrant. For purposes of clarity, the shares of Common Stock issuable pursuant to the terms of this Warrant in excess of the Maximum Percentage
shall not be deemed to be beneficially owned by the Holder or the Attribution Parties for any purpose including for purposes of Section&nbsp;13(d) of the Exchange Act and the rules promulgated thereunder or Section&nbsp;16 of the Exchange Act and
the rules promulgated thereunder, including Rule <FONT STYLE="white-space:nowrap">16a-1(a)(1).</FONT> No prior inability to exercise this Warrant pursuant to this paragraph shall have any effect on the applicability of the provisions of this
paragraph with respect to any subsequent determination of exercisability. The provisions of this paragraph shall be construed and implemented in a manner otherwise than in strict conformity with the terms of this
<U>Section</U><U></U><U>&nbsp;11(a)</U> to the extent necessary to correct this paragraph or any portion of this paragraph which may be defective or inconsistent with the intended beneficial ownership limitation contained in this
<U>Section</U><U></U><U>&nbsp;11(a)</U> or to make changes or supplements necessary or desirable to properly give effect to such limitation. The limitation contained in this paragraph may not be waived and shall apply to a successor holder of this
Warrant.<B> </B> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">12. <I>No Fractional Shares</I>. No fractional Warrant Shares will be issued in connection with any exercise of this Warrant. In lieu of
any fractional shares that would otherwise be issuable, the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in cash the fair market value (based on the Closing Sale Price) for
any such fractional shares. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">13. <I>Notices</I>. Any and all notices or other communications or deliveries hereunder (including, without limitation, any
Exercise Notice) shall be in writing and shall be deemed given and effective on the earliest of (i)&nbsp;the date of transmission, if such notice or communication is delivered confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the <FONT
STYLE="white-space:nowrap">e-mail</FONT> address specified in the books and records of the Transfer Agent prior to 5:30 P.M., New York City time, on a Trading Day, (ii)&nbsp;the next Trading Day after the date of transmission, if such notice or
communication is delivered via confirmed <FONT STYLE="white-space:nowrap">e-mail</FONT> at the <FONT STYLE="white-space:nowrap">e-mail</FONT> address specified in the books and records of the Transfer Agent on a day that is not a Trading Day or
later than 5:30 P.M., New York City time, on any Trading Day, (iii)&nbsp;the Trading Day following the date of mailing, if sent by nationally recognized overnight courier service specifying next business day delivery, or (iv)&nbsp;upon actual
receipt by the Person to whom such notice is required to be given, if by hand delivery. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">14. <I>Warrant Agent</I>. The Company shall initially serve as
warrant agent under this Warrant. Upon thirty (30)&nbsp;days&#146; notice to the Holder, the Company may appoint a new warrant agent. Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any
consolidation to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent transfers substantially all of its corporate trust or shareholders services business shall be a successor
warrant agent under this Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent to be mailed (by first class mail, postage prepaid) to the Holder at the Holder&#146;s last
address as shown on the Warrant Register. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">15. <I>Miscellaneous</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a) <U>No Rights as a Stockholder</U>. Except as otherwise set forth in this Warrant, the Holder, solely in such Person&#146;s capacity as a
holder of this Warrant, shall not be entitled to vote or receive dividends or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed to confer upon the Holder, solely in such
Person&#146;s capacity as the Holder of this Warrant, any of the rights of a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
stockholder of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock, reclassification of stock, consolidation, merger,
amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares which such Person is then entitled to receive upon the due exercise
of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the Company, whether such
liabilities are asserted by the Company or by creditors of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b) <U>Authorized Shares</U>. (i)&nbsp;Except and to the extent
as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking
of all such actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without limiting the generality of the foregoing, the Company will (a)&nbsp;not increase the par value of any
Warrant Shares above the amount payable therefor upon such exercise immediately prior to such increase in par value, (b)&nbsp;take all such action as may be necessary or appropriate in order that the Company may validly and legally issue fully paid
and <FONT STYLE="white-space:nowrap">non-assessable</FONT> Warrant Shares upon the exercise of this Warrant, and (c)&nbsp;use commercially reasonable efforts to obtain all such authorizations, exemptions or consents from any public regulatory body
having jurisdiction thereof as may be necessary to enable the Company to perform its obligations under this Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(ii) Before taking any action which
would result in an adjustment in the number of Warrant Shares for which this Warrant is exercisable or in the Exercise Price, the Company shall obtain all such authorizations or exemptions thereof, or consents thereto, as may be necessary from any
public regulatory body or bodies having jurisdiction thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c) <U>Successors and Assigns</U>. Subject to compliance with applicable
securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant shall be binding on
and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder any legal
or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed by the Company and the Holder, or their successors and assigns. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d) <U>Amendment and Waiver</U>. Except as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take
any action herein prohibited, or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(e) <U>Acceptance</U>. Receipt of this Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions
contained herein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(f) <U>Governing Law; Jurisdiction</U>. ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND
INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY
SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH ANY TRANSACTION CONTEMPLATED HEREBY OR
DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS), AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY SUBJECT TO THE
JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR
CERTIFIED MAIL OR OVERNIGHT DELIVERY </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
(WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF.
NOTHING CONTAINED HEREIN SHALL BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY WAIVES ALL RIGHTS TO A TRIAL BY JURY. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(g) <U>Headings</U>. The headings herein are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit
or affect any of the provisions hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(h) <U>Severability</U>. In case any one or more of the provisions of this Warrant shall be
invalid or unenforceable in any respect, the validity and enforceability of the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the Holder will attempt in good faith to agree
upon a valid and enforceable provision which shall be a commercially reasonable substitute therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the Company has caused this Warrant to be duly executed by its
authorized officer as of the date first indicated above. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="12%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">MONTE ROSA THERAPEUTICS, INC.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD></TR>
</TABLE></DIV>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SCHEDULE 1<U></U> </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM OF EXERCISE NOTICE </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[To
be executed by the Holder to purchase shares of Common Stock under the Warrant] </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(1) The undersigned is the Holder of Warrant No. <U>&#8195;</U> (the &#147;Warrant&#148;) issued by Monte Rosa Therapeutics, Inc., a Delaware corporation (the
&#147;Company&#148;). Capitalized terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(2) The
undersigned hereby exercises its right to purchase Warrant Shares pursuant to the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(3) The Holder intends that payment of the Exercise Price
shall be made as (check one): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744; Cash Exercise </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#9744; &#147;Cashless Exercise&#148; under Section&nbsp;10 of the Warrant </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(4) If the Holder has elected a Cash Exercise, the Holder shall pay the sum of $<U>&#8195;&#8195;</U> in immediately available funds to the Company in
accordance with the terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(5) Pursuant to this Exercise Notice, the Company shall deliver to the Holder Warrant Shares determined in
accordance with the terms of the Warrant. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">(6) By its delivery of this Exercise Notice, the undersigned represents and warrants to the Company that in
giving effect to the exercise evidenced hereby the Holder will not beneficially own in excess of the number of shares of Common Stock (as determined in accordance with Section&nbsp;13(d) of the Securities Exchange Act of 1934, as amended) permitted
to be owned under Section<U></U>&nbsp;11(a) of the Warrant to which this notice relates. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="33%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="66%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dated:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name&nbsp;of&nbsp;Holder:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(Signature must conform in all respects to name of Holder as specified on the face of the Warrant) </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>d512767dex51.htm
<DESCRIPTION>EX-5.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-5.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 5.1 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>

<TD WIDTH="35%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="32%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="31%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt;margin-bottom:1pt; margin-left:1.00em; text-indent:-1.00em">


<IMG SRC="g512767g1026185941264.jpg" ALT="LOGO">
</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">100 Northern Avenue
<BR>Boston, MA 02210</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">goodwinlaw.com</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">+1 617 570
1000</P></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">October&nbsp;26, 2023 </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monte Rosa Therapeutics, Inc. </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">321 Harrison Avenue, Suite 900
</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Boston, MA 02118 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman">Re: <U>Securities
Registered under Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT></U> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Ladies and Gentlemen: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have acted as counsel to you in connection with your filing of a Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> <FONT
STYLE="white-space:nowrap">(File&nbsp;No.&nbsp;333-266003)</FONT> (the &#147;<U>Registration Statement</U>&#148;) filed on July&nbsp;1, 2022 with the Securities and Exchange Commission (the &#147;<U>Commission</U>&#148;) pursuant to the Securities
Act of 1933, as amended (the &#147;<U>Securities Act</U>&#148;), relating to the registration of the offer by Monte Rosa Therapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;) of up to $300,000,000 of any combination of
securities of the types specified therein. The Registration Statement was declared effective by the Commission on July&nbsp;13, 2022. Reference is made to our opinion letter dated July&nbsp;1, 2022 and included as Exhibit 5.1 to the Registration
Statement. We are delivering this supplemental opinion letter in connection with the prospectus supplement (the &#147;<U>Prospectus Supplement</U>&#148;) filed on October&nbsp;26, 2023 by the Company with the Commission pursuant to Rule 424 under
the Securities Act. The Prospectus Supplement relates to the offering by the Company of up to 10,000,400 shares of the Company&#146;s Common Stock, par value $0.0001 per share (the &#147;<U>Common Stock</U>&#148;), issuable upon the exercise of <FONT
STYLE="white-space:nowrap">pre-funded</FONT> warrants (the &#147;<U><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</U>&#148; and the shares issuable upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, the
&#147;<U>Shares</U>&#148;) covered by the Registration Statement. The Pre-Funded Warrants are being sold to the several purchasers named in, and pursuant to, a securities purchase agreement among the Company and such purchasers (the
&#147;<U>Securities Purchase Agreement</U>&#148;). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have reviewed such documents and made such examination of law as we have deemed appropriate to give
the opinion set forth below. We have relied, without independent verification, on certificates of public officials and, as to matters of fact material to the opinion set forth below, on certificates of officers of the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The opinions set forth below are limited to the Delaware General Corporation Law and New York law (without regard to the possible application under New York
choice-of-law rules of the substantive law of any other jurisdiction). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Based on the foregoing, we are of the opinion that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">The <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants have been duly authorized and, when delivered
and paid for in accordance with the terms of the Securities Purchase Agreement, will be valid and binding obligations of the Company. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman; " ALIGN="left">Assuming sufficient authorized but unissued shares of Common Stock are available for issuance when the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants are exercised, the Shares, when and if issued upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in accordance with the terms of the
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants, will be validly issued, fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our opinions set forth above are subject to the following additional qualifications: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(a)&#8195;Our opinion set forth above as to enforceability is subject to and limited by the effect of any applicable bankruptcy, insolvency,
fraudulent transfer, reorganization, moratorium and other similar laws of general application affecting the rights and remedies of creditors and to general principles of equity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(b)&#8195;We express no opinion with respect to any provision of any of the Pre-Funded Warrants relating to: (i) non-reliance, exculpation,
disclaimer, limitation of liability, indemnification, contribution, waiver, limitation or exclusion of remedies; (ii) liquidated damages, forfeitures, default interest, late charges, make-whole premiums, payment of attorneys&#146; fees, collection
upon acceleration of amounts that might be determined to constitute unearned interest thereon, or other economic remedies, in each case to the extent it constitutes a penalty or is prohibited by law; (iii) concepts of materiality, reasonableness,
good faith, fair dealing or unconscionability; (iv) governing law (except for the enforceability of any provision choosing New York law as the Pre-Funded Warrants&#146; governing law pursuant to the statutes referred to in paragraph (c) below); (v)
the waiver of the right to trial by jury or of usury, stay, extension and similar laws; (vi) rights or remedies not being exclusive, not preventing the concurrent assertion of any other right or remedy, being cumulative and exercisable in addition
to any other right and remedy, or any delay or omission to exercise any right or remedy not impairing any right or remedy or not constituting a waiver thereof; (viii) any obligation or agreement to use best efforts, reasonable best efforts or
commercially reasonable efforts; (ix) any requirement that a party take further action or enter into further agreements or instruments or provide further assurances; (x) any requirement that amendments or waivers be in writing insofar as they
suggest that oral or other modifications, amendments or waivers could not be effectively agreed upon by the parties or that the doctrine of promissory estoppel might not apply; (xi) service of process by any method not provided for under applicable
statute or court rule; and (xii) the severability of any provisions to the foregoing effect to the extent such provisions are unenforceable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(c)&#8195;To the extent that any opinion set forth herein relates to the enforceability of choice of New York law, choice of New York forum or
exclusive jurisdiction provisions in the Pre-Funded Warrants, such opinion is rendered solely in reliance upon N.Y. Gen. Oblig. Law &#167;&#167; 5-1401, 5-1402 (McKinney 2010) and N.Y. CPLR 327(b) (McKinney 2010) and is subject to the qualification
that such enforceability may be limited by public policy or other considerations of any jurisdiction, other than the State of New York, in which enforcement of such provisions, or of a judgment upon an agreement containing such provisions, is sought
and by constitutional limitations. With respect to waiving any objection to venue, our opinion is qualified in its entirety by N.Y. CPLR 510 (McKinney 2010). We call your attention that courts of the State of New York, or federal courts of the
United&nbsp;States of America located in New&nbsp;York, could decline to hear a case on grounds of forum non conveniens or similar doctrines limiting the availability of such courts as a forum for the resolution of disputes, irrespective of any
agreement between the parties concerning jurisdiction. We express no opinion as to (i) any waiver of objections based on inconvenient forum or (ii) venue or the subject matter jurisdiction of the federal courts of the United States. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(d)&#8195;Our opinions set forth above do not cover, without limitation, the following: the Defense Production Act of 1950, as amended, and
the Foreign Investment Risk Review Modernization Act of 2018, including all implementing regulations thereunder, banking, tax, antitrust, trade regulation, anti-fraud or unfair competition laws; insolvency or fraudulent transfer; compliance with
fiduciary duty requirements; pension or employee benefits; environmental or energy laws; Financial Industry Regulatory rules; stock exchange rules; consumer protection laws; utilities laws; foreign trade, national security, anti-terrorism,
anti-money laundering laws; laws regulating derivatives, investment and brokerage services; or other laws customarily understood to be excluded even though they are not expressly stated to be excluded, except to the extent expressly covered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This opinion letter and the opinion it contains shall be interpreted in accordance with the Core Opinion Principles as published in 74 <I>Business Lawyer</I>
815 (Summer 2019). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We hereby consent to the inclusion of this opinion as Exhibit 5.1 to the Company&#146;s Current Report on Form <FONT
STYLE="white-space:nowrap">8-K</FONT> dated October&nbsp;26, 2023 and to the references to our firm under the caption &#147;Legal Matters&#148; in the Registration Statement. In giving our consent, we do not admit that we are in the category of
persons whose consent is required under Section&nbsp;7 of the Securities Act or the rules and regulations thereunder. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monte Rosa Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">October&nbsp;26, 2023 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Page 2 </P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="100%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Very truly yours,</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">/s/ Goodwin Procter LLP</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">GOODWIN PROCTER LLP</TD></TR>
</TABLE></DIV>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>4
<FILENAME>d512767dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><U>SECURITIES PURCHASE AGREEMENT </U></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This SECURITIES PURCHASE AGREEMENT (this &#147;<U>Agreement</U>&#148;) is made and entered into as of October&nbsp;26, 2023, by and among
Monte Rosa Therapeutics, Inc., a Delaware corporation (the &#147;<U>Company</U>&#148;), and the Investors identified on <U>Exhibit A</U> attached hereto (each an &#147;<U>Investor</U>&#148; and collectively the &#147;<U>Investors</U>&#148;). </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A. The
Investors wish to purchase from the Company, and the Company wishes to sell and issue to the Investors, upon the terms and subject to the conditions stated in this Agreement and pursuant to an effective registration statement under the 1933 Act (as
defined below), <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase shares of the Company&#146;s Common Stock, par value $0.0001 per share, in the form attached hereto as <U>Exhibit B</U> (each, a &#147;<U><FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant</U>&#148; and collectively, the &#147;<U><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</U>&#148;); and </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In consideration of the mutual promises made herein and for other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto agree as follows: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">1. <U>Definitions</U>. For the purposes of this Agreement, the following terms
shall have the meanings set forth below: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Affiliate</U>&#148; means, with respect to any Person, any other Person which directly
or indirectly through one or more intermediaries Controls, is controlled by, or is under common Control with such Person. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Agreement</U>&#148; has the meaning set forth in the first paragraph. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Business Day</U>&#148; means a day, other than a Saturday or Sunday, on which banks in New York City are open for the general
transaction of business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Bylaws</U>&#148; means the Amended and Restated <FONT STYLE="white-space:nowrap">By-laws</FONT> of the
Company, as in effect of the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Certificate of Incorporation</U>&#148; means the Fourth Amended and Restated
Certificate of Incorporation of the Company, as amended, as in effect on the date hereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing</U>&#148; has the meaning set
forth in Section&nbsp;3.1. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Closing Date</U>&#148; has the meaning set forth in Section&nbsp;3.1. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock</U>&#148; has the meaning set forth in the recitals to this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Common Stock Equivalents</U>&#148; means any securities of the Company which would entitle the holder thereof to acquire at any time
Common Stock, including, without limitation, any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company</U>&#148; has the meaning set forth in the first paragraph. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Company&#146;s Knowledge</U>&#148; means the actual knowledge of the executive
officers (as defined in Rule&nbsp;405 under the 1933 Act) of the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Control</U>&#148; (including the terms
&#147;controlling,&#148; &#147;controlled by&#148; or &#147;under common control with&#148;) means the possession, direct or indirect, of the power to direct or cause the direction of the management and policies of a Person, whether through the
ownership of voting securities, by contract or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Disqualification Event</U>&#148; has the meaning set forth in
Section&nbsp;4.33. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>EDGAR system</U>&#148; has the meaning set forth in Section&nbsp;4.9. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Environmental Laws</U>&#148; has the meaning set forth in Section&nbsp;4.15. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>GAAP</U>&#148; has the meaning set forth in Section&nbsp;4.17. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Intellectual Property</U>&#148; has the meaning set forth in Section&nbsp;4.14. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Investor</U>&#148; has the meaning set forth in the first paragraph. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Adverse Effect</U>&#148; means a material adverse effect on (i)&nbsp;the assets, liabilities, results of operations,
financial condition or business of the Company taken as a whole, (ii)&nbsp;the legality or enforceability of any of the Transaction Documents or (iii)&nbsp;the ability of the Company to perform its obligations under the Transaction Documents, except
that for purposes of Section&nbsp;6.1(i) of this Agreement, in no event shall a change in the market price of the Common Stock alone constitute a &#147;Material Adverse Effect.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Material Contract</U>&#148; means any contract, instrument or other agreement to which the Company is a party or by which it is bound
that has been filed or was required to have been filed as an exhibit to the SEC Filings pursuant to Item&nbsp;601(b)(4) or Item 601(b)(10) of <FONT STYLE="white-space:nowrap">Regulation&nbsp;S-K.</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Nasdaq</U>&#148; means the Nasdaq Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Person</U>&#148; means an individual, corporation, partnership, limited liability company, trust, business trust, association, joint
stock company, joint venture, sole proprietorship, unincorporated organization, governmental authority or any other form of entity not specifically listed herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Placement Securities</U>&#148; means the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U><FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants</U>&#148; has the meaning set forth in the recitals to this Agreement.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Principal Trading Market</U>&#148; means the Trading Market on which the Common Stock is primarily listed on and quoted for
trading, which, as of the date of this Agreement and the Closing Date, shall be the Nasdaq Global Select Market. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Prospectus</U>&#148; means the prospectus included in the Registration Statement, at the time it was declared effective by the
Commission. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Prospectus Supplement</U>&#148; means the supplement to the Prospectus complying with Rule 424(b) of the 1933 Act
that is filed with the Commission and delivered by the Company to each Investor on or prior to the date hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Registration Statement</U>&#148; means the effective registration statement with
Commission file <FONT STYLE="white-space:nowrap">No.&nbsp;333-266003</FONT> which registers the sale of the Warrant Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Regulatory Authorities</U>&#148; has the meaning set forth in Section&nbsp;4.30. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC</U>&#148; means the U.S. Securities and Exchange Commission. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>SEC Filings</U>&#148; has the meaning set forth in Section&nbsp;4.8. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Securities</U>&#148; means the Placement Securities and the Warrant Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Short Sales</U>&#148; means all &#147;short sales&#148; as defined in Rule 200 of Regulation SHO under the 1934 Act (but shall not be
deemed to include the location and/or reservation of borrowable shares of Common Stock). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Day</U>&#148; means (i)&nbsp;a
day on which the Common Stock is listed or quoted and traded on its Principal Trading Market or (ii)&nbsp;if the Common Stock is not quoted on any Trading Market, a day on which the Common Stock is quoted in the <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market as reported in the &#147;pink sheets&#148; by OTC Markets Group Inc. (or any similar organization or agency succeeding to its functions of reporting prices); provided, that in the
event that the Common Stock is not listed or quoted as set forth in (i)&nbsp;or (ii) hereof, then Trading Day shall mean a Business Day. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Trading Market</U>&#148; means whichever of the New York Stock Exchange, the NYSE American, the Nasdaq Global Select Market, the
Nasdaq Global Market or the Nasdaq Capital Market on which the Common Stock is listed or quoted for trading on the date in question. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Transaction Documents</U>&#148; means this Agreement, the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants and the
Prospectus Supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>Warrant Shares</U>&#148; means the shares of Common Stock issuable upon exercise of the <FONT
STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>1933 Act</U>&#148; means the Securities Act of 1933, as amended, or any
successor statute, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;<U>1934 Act</U>&#148; means the Securities Exchange Act of
1934, as amended, or any successor statute, and the rules and regulations promulgated thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">2. <U>Purchase and Sale of the
Placement Securities</U>. On the Closing Date, upon the terms and subject to the conditions set forth herein, the Company will issue and sell, and the Investors will purchase, severally and not jointly, a
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant to purchase the number of Warrant Shares set forth opposite the name of such Investor under the heading &#147;Number of Warrant Shares Underlying
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Purchased&#148; on <U>Exhibit A</U> attached hereto. The purchase price per <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant shall be $2.4999. The
<FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants shall have an exercise price equal to $0.0001 per Warrant Share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">3.
<U>Closing</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.1. Upon the satisfaction of the conditions set forth in <U>Section</U><U></U><U>&nbsp;6</U>, the completion of the
purchase and sale of the Placement Securities (the &#147;<U>Closing</U>&#148;) shall occur remotely via exchange of documents and signatures at a time (the &#147;<U>Closing Date</U>&#148;) to be agreed to by the Company and the Investors but
(i)&nbsp;in no event earlier than the second Business Day after the date hereof and (ii)&nbsp;in no event later than the third Trading Day after the date hereof. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.2. On or before the Closing Date, each Investor shall deliver or cause to be delivered to
the Company, via wire transfer of immediately available funds pursuant to the wire instructions delivered to such Investor by the Company on or prior to the Closing Date, an amount equal to the purchase price to be paid by the Investor for the
Placement Securities to be acquired by it as set forth opposite the name of such Investor under the heading &#147;Aggregate Purchase Price of Placement Securities&#148; on <U>Exhibit A</U> attached hereto. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">3.3. At the Closing, the Company shall deliver or cause to be delivered to each Investor a <FONT STYLE="white-space:nowrap">Pre-Funded</FONT>
Warrant, registered in the name of the Investor (or its nominee in accordance with its delivery instructions), to purchase up to the number of Warrant Shares set forth opposite the name of such Investor under the heading &#147;Number of Warrant
Shares Underlying <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant Purchased&#148; on <U>Exhibit A</U> attached hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">4.
<U>Representations and Warranties of the Company</U>. The Company hereby represents and warrants to the Investors that, except as described in the Company&#146;s SEC Filings (excluding (i)&nbsp;any exhibits to any Company SEC Filings and
(ii)&nbsp;any risk factor disclosures contained under the heading &#147;Risk Factors&#148; and any disclosure of risks included in any &#147;forward-looking statements&#148; disclaimer), each of which qualify the representations and warranties below
in their entirety. For purposes of these representations and warranties, the term the &#147;Company&#148; shall include any subsidiaries of the Company, unless otherwise noted herein. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.1. <U>Organization, Good Standing and Qualification</U>. The Company is a corporation duly organized, validly existing and in good standing
under the laws of the jurisdiction of its incorporation and has all requisite corporate power and authority to carry on its business as now conducted and to own or lease its properties. The Company is duly qualified to do business as a foreign
corporation and is in good standing in each jurisdiction in which the conduct of its business or its ownership or leasing of property makes such qualification or leasing necessary unless the failure to so qualify has not had and would not reasonably
be expected to have a Material Adverse Effect. The Company does not currently own or control, directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business
entity. The Company is not a participant in any joint venture, partnership or similar arrangement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.2. <U>Authorization</U>. The Company
has the requisite corporate power and authority and has taken all requisite corporate action necessary for, and no further action on the part of the Company, its officers, directors and stockholders is necessary for, (i)&nbsp;the authorization,
execution and delivery of the Transaction Documents, (ii)&nbsp;the authorization of the performance of all obligations of the Company hereunder or thereunder, and (iii)&nbsp;the authorization, issuance (or reservation for issuance) and delivery of
the Placement Securities. The Transaction Documents constitute the legal, valid and binding obligations of the Company, enforceable against the Company in accordance with their terms, subject to bankruptcy, insolvency, fraudulent transfer,
reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors&#146; rights generally and to general equitable principles. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.3. <U>Capitalization</U>. The Company is authorized under its Certificate of Incorporation to issue 500,000,000 shares of Common Stock and
10,000,000 shares of undesignated Preferred Stock. The Company&#146;s disclosure of its issued and outstanding capital stock in its most recent SEC Filing containing such disclosure was accurate in all material respects as of the date indicated in
such SEC Filing. All of the issued and outstanding shares of the Company&#146;s capital stock have been duly authorized and validly issued and are fully paid and nonassessable; none of such shares were issued in
</P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
violation of any preemptive rights; and such shares were issued in compliance in all material respects with applicable state and federal securities law and any rights of third parties. No Person
is entitled to preemptive or similar statutory or contractual rights with respect to the issuance by the Company of any securities of the Company, including, without limitation, the Placement Securities. Except for stock options and restricted stock
units approved pursuant to the Company stock-based compensation plans described in the SEC Filings, there are no outstanding warrants, options, convertible securities or other rights, agreements or arrangements of any character under which the
Company is or may be obligated to issue any equity securities of any kind, except as contemplated by this Agreement. There are no voting agreements, <FONT STYLE="white-space:nowrap">buy-sell</FONT> agreements, option or right of first purchase
agreements or other similar agreements among the Company and any of the securityholders of the Company relating to the securities of the Company held by them. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The issuance and sale of the Placement Securities hereunder will not obligate the Company to issue shares of Common Stock or other securities
to any other Person (other than the Investors) and will not result in the adjustment of the exercise, conversion, exchange or reset price of any outstanding security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">The Company does not have outstanding stockholder purchase rights or a &#147;poison pill&#148; or any similar arrangement in effect giving any
Person the right to purchase any equity interest in the Company upon the occurrence of certain events. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.4. <U>Valid Issuance;
Registration</U>. The Warrant Shares have been duly and validly authorized and reserved for issuance and, upon exercise of the <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrants in accordance with their terms, including the payment of any
exercise price therefor, will be validly issued, fully paid and nonassessable and will be free and clear of all encumbrances and restrictions (other than those created by the Investors), except for restrictions on transfer set forth in the
Transaction Documents or imposed by applicable securities laws. The Company has prepared and filed the Registration Statement in conformity with the requirements of the 1933 Act, including the Prospectus, and such amendments and supplements thereto
as may have been required to the date of this Agreement. The Registration Statement is effective under the 1933 Act and no stop order preventing or suspending the effectiveness of the Registration Statement or suspending or preventing the use of the
Prospectus has been issued by the Commission and no proceedings for that purpose have been instituted or, to the knowledge of the Company, are threatened in writing by the Commission. The Company, if required by the rules and regulations of the
Commission, shall file the Prospectus Supplement with the Commission pursuant to Rule 424(b). At the time the Registration Statement and any post-effective amendments thereto became effective, at the date of this Agreement and at the Closing Date,
the Registration Statement and any amendments thereto conformed and will conform in all material respects to the requirements of the 1933 Act and did not and will not contain any untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein not misleading; and the Prospectus Supplement and any amendments or supplements thereto, at the time the Prospectus Supplement or any amendment or supplement thereto was
issued and at the Closing Date, conformed and will conform in all material respects to the requirements of the 1933 Act and did not and will not contain an untrue statement of a material fact or omit to state a material fact necessary in order to
make the statements therein, in the light of the circumstances under which they were made, not misleading. The Company is eligible to use Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the 1933 Act and it meets the transaction requirements
as set forth in General Instruction I.B.1 of Form <FONT STYLE="white-space:nowrap">S-3.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.5. <U>Consents</U>. Subject to the
accuracy of the representations and warranties of each Investor set forth in Section&nbsp;5 hereof, the execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and sale of the Placement Securities
require no consent of, action by or in respect of, or filing with, any Person, governmental body, agency, or official other than (a) </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
filings that have been made pursuant to applicable state securities laws, (b)&nbsp;post-sale filings pursuant to applicable state and federal securities laws, and (c)&nbsp;filings pursuant to the
rules and regulations of Nasdaq, each of which the Company has filed or undertakes to file within the applicable time. Subject to the accuracy of the representations and warranties of each Investor set forth in Section&nbsp;5 hereof, the Company has
taken all action necessary to exempt (i)&nbsp;the issuance and sale of the Placement Securities and (ii)&nbsp;the other transactions contemplated by the Transaction Documents from the provisions of any stockholder rights plan or other &#147;poison
pill&#148; arrangement, any anti-takeover, business combination or control share law or statute binding on the Company or to which the Company or any of its assets and properties is subject that is or could reasonably be expected to become
applicable to the Investors as a result of the transactions contemplated hereby, including without limitation, the issuance of the Placement Securities and the ownership, disposition or voting of the Warrant Shares by the Investors or the exercise
of any right granted to the Investors pursuant to this Agreement or the other Transaction Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.6. <U>Use of Proceeds</U>. The net
proceeds of the sale of the Placement Securities hereunder shall be used by the Company for working capital and general corporate purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.7. <U>No Material Adverse Change</U>. Since June&nbsp;30, 2023, except as identified and described in the SEC Filings, there has not been:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) any change in the assets, liabilities, financial condition or operating results of the Company from that reflected in the financial
statements included in the Company&#146;s Quarterly Report on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarter ended June&nbsp;30, 2023, except for changes in the ordinary course of business which have not had and would not
reasonably be expected to have a Material Adverse Effect, individually or in the aggregate; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) any declaration or payment by the
Company of any dividend, or any authorization or payment by the Company of any distribution, on any of the capital stock of the Company, or any redemption or repurchase by the Company of any securities of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) any material damage, destruction or loss, whether or not covered by insurance, to any assets or properties of the Company; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) any waiver, not in the ordinary course of business, by the Company of a material right or of a material debt owed to it; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(v) any satisfaction or discharge of any lien, claim or encumbrance or payment of any obligation by the Company, except in the ordinary
course of business and which is not material to the assets, properties, financial condition, operating results or business of the Company (as such business is presently conducted); </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vi) any change or amendment to the Company&#146;s Certificate of Incorporation or Bylaws, or material change to any material contract or
arrangement by which the Company is bound or to which any of its assets or properties is subject; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(vii) any material labor difficulties
or, to the Company&#146;s Knowledge, labor union organizing activities with respect to employees of the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(viii) any material
transaction entered into by the Company other than in the ordinary course of business; </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ix) the loss of the services of any key employee, or material change in the composition or
duties of the senior management of the Company; or </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(x) any other event or condition of any character that has had or would reasonably be
expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.8. <U>SEC Filings</U>. The Company has filed all reports, schedules, forms, statements and
other documents required to be filed by the Company under the 1933 Act and the 1934 Act, including pursuant to Section&nbsp;13(a) or 15(d) thereof, for the one year period preceding the date hereof (or such shorter period as the Company was required
by law or regulation to file such material) (collectively, the &#147;<U>SEC Filings</U>&#148;). At the time of filing thereof, the SEC Filings complied in all material respects with the requirements of the 1933 Act or the 1934 Act, as applicable,
and the rules and regulations of the SEC thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.9. <U>No Conflict, Breach, Violation or Default</U>. The execution, delivery and
performance of the Transaction Documents by the Company and the issuance and sale of the Placement Securities in accordance with the provisions thereof will not, except (solely in the case of clauses (i)(b) and (ii)) for such violations, conflicts
or defaults as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect, (i)&nbsp;conflict with or result in a breach or violation of (a)&nbsp;any of the terms and provisions of, or constitute a default
under, the Company&#146;s Certificate of Incorporation or the Company&#146;s Bylaws, both as in effect on the date hereof (true and complete copies of which have been made available to the Investors through the Electronic Data Gathering, Analysis,
and Retrieval system (the &#147;<U>EDGAR system</U>&#148;)), or (b)&nbsp;assuming the accuracy of the representations and warranties in Section&nbsp;5, any applicable statute, rule, regulation or order of any governmental agency or body or any
court, domestic or foreign, having jurisdiction over the Company, or any of its assets or properties, or (ii)&nbsp;conflict with, or constitute a default (or an event that with notice or lapse of time or both would become a default) under, result in
the creation of any lien, encumbrance or other adverse claim upon any of the properties or assets of the Company or give to others any rights of termination, amendment, acceleration or cancellation (with or without notice, lapse of time or both) of,
any Material Contract. This Section&nbsp;4.9 does not relate to matters with respect to tax status, which are the subject of Section&nbsp;4.10, employee relations and labor matters, which are the subject of Section&nbsp;4.13, or environmental
matters, which are the subject of Section&nbsp;4.15. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.10. <U>Tax Matters</U>. The Company has timely prepared and filed all material tax
returns required to have been filed by it with all appropriate governmental agencies and timely paid all material taxes shown thereon or otherwise owed by it.&nbsp;There are no material unpaid assessments against the Company nor, to the
Company&#146;s Knowledge, any audits by any federal, state or local taxing authority.&nbsp;All material taxes that the Company is required to withhold or to collect for payment have been duly withheld and collected and paid to the proper
governmental entity or third party when due.&nbsp;There are no tax liens pending or, to the Company&#146;s Knowledge, threatened against the Company or any of its assets or property.&nbsp;With the exception of agreements or other arrangements that
are not primarily related to taxes entered into in the ordinary course of business, there are no outstanding tax sharing agreements or other such arrangements between the Company and any other corporation or entity. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.11. <U>Title to Properties</U>. The Company has good and marketable title to all real properties and all other material properties and
assets owned by it, in each case free from liens, encumbrances and defects, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect; and the Company holds any leased real or personal
property under valid and enforceable leases with no exceptions, except such as would not reasonably be expected, individually or in the aggregate, to have a Material Adverse Effect. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.12. <U>Certificates, Authorities and Permits</U>. The Company possesses adequate
certificates, authorities or permits issued by appropriate governmental agencies or bodies necessary to conduct the business now operated by it, except where failure to so possess would not reasonably be expected, individually or in the aggregate,
to result in a Material Adverse Effect. The Company has not received any written notice of proceedings relating to the revocation or modification of any such certificate, authority or permit that would reasonably be expected to have a Material
Adverse Effect, individually or in the aggregate, on the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.13. <U>Labor Matters</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The Company is not party to or bound by any collective bargaining agreements or other agreements with labor organizations. To the
Company&#146;s Knowledge, the Company has not violated in any material respect any laws, regulations, orders or contract terms affecting the collective bargaining rights of employees or labor organizations, or any laws, regulations or orders
affecting employment discrimination, equal opportunity employment, or employees&#146; health, safety, welfare, wages and hours. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) No
material labor dispute with the employees of the Company, or with the employees of any principal supplier, manufacturer, customer or contractor of the Company, exists or, to the Company&#146;s Knowledge, is threatened or imminent. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.14. <U>Intellectual Property</U>. The Company owns, possesses, licenses or has other rights to use, all patents, patent applications, trade
and service marks, trade and service mark registrations, trade names, copyrights, licenses, inventions, trade secrets, technology, <FONT STYLE="white-space:nowrap">know-how</FONT> and other intellectual property (collectively, the
&#147;<U>Intellectual Property</U>&#148;) necessary for the conduct of the Company&#146;s business in all material respects as now conducted or as proposed in the SEC Filings to be conducted; and (a)&nbsp;there are no rights of third parties to any
such Intellectual Property, including no liens, security interests or other encumbrances; (b)&nbsp;to the Company&#146;s Knowledge, there is no material infringement by third parties of any such Intellectual Property; (c)&nbsp;there is no pending
or, to the Company&#146;s Knowledge, threatened action, suit, proceeding or claim by others challenging the Company&#146;s rights in or to any such Intellectual Property; (d)&nbsp;such Intellectual Property that is described in the SEC Filings has
not been adjudged by a court of competent jurisdiction invalid or unenforceable, in whole or in part; (e)&nbsp;there is no pending or, to the Company&#146;s Knowledge, threatened action, suit, proceeding or claim by others challenging the validity
or scope of any such Intellectual Property that is owned or licensed by the Company, including interferences, oppositions, reexaminations or government proceedings; (f)&nbsp;there is no pending or, to the Company&#146;s Knowledge, threatened action,
suit, proceeding or claim by others that the Company infringes, misappropriates, or otherwise violates any patent, trademark, copyright, trade secret or other proprietary rights of others; and (g)&nbsp;to the Company&#146;s Knowledge, each Company
employee involved with the development of Intellectual Property has entered into an invention assignment agreement with the Company. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.15. <U>Environmental Matters</U>. The Company is not in violation of any statute, rule, regulation, decision or order of any governmental
agency or body or any court, domestic or foreign, relating to the use, disposal or release of hazardous or toxic substances or relating to the protection or restoration of the environment or human exposure to hazardous or toxic substances
(collectively, &#147;<U>Environmental Laws</U>&#148;), has not released any hazardous substances regulated by Environmental Laws onto any real property that it owns or operates and has not received any written notice or claim it is liable for any <FONT
STYLE="white-space:nowrap">off-site</FONT> disposal or contamination pursuant to any Environmental Laws, which violation, release, notice, claim, or liability would reasonably be expected, individually or in the aggregate, to have a Material Adverse
Effect, and to the Company&#146;s Knowledge, there is no pending or threatened investigation that would reasonably be expected to lead to such a claim. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.16. <U>Legal Proceedings</U>. There are no legal, governmental or regulatory
investigations, actions, suits or proceedings pending to which the Company is or may reasonably be expected to become a party or to which any property of the Company is or may reasonably be expected to become the subject that, individually or in the
aggregate, would reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.17. <U>Financial Statements</U>. The financial statements
included in each SEC Filing comply in all material respects with applicable accounting requirements and the rules and regulations of the SEC with respect thereto as in effect at the time of filing (or to the extent corrected by a subsequent
restatement) and present fairly, in all material respects, the financial position of the Company as of the dates shown and its results of operations and cash flows for the periods shown, subject in the case of unaudited financial statements to
normal, immaterial <FONT STYLE="white-space:nowrap">year-end</FONT> audit adjustments, and such financial statements have been prepared in conformity with United States generally accepted accounting principles applied on a consistent basis during
the periods involved (&#147;<U>GAAP</U>&#148;) (except as may be disclosed therein or in the notes thereto, and except that the unaudited financial statements may not contain all footnotes required by GAAP, and, in the case of quarterly financial
statements, except as permitted by Form <FONT STYLE="white-space:nowrap">10-Q</FONT> under the 1934 Act). Except as set forth in the financial statements of the Company included in the SEC Filings filed prior to the date hereof, the Company has not
incurred any liabilities, contingent or otherwise, except those incurred in the ordinary course of business, consistent (as to amount and nature) with past practices since the date of such financial statements, none of which, individually or in the
aggregate, have had or would reasonably be expected to have a Material Adverse Effect. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.18. <U>Insurance Coverage</U>. The Company
maintains in full force and effect insurance coverage that is customary for comparably situated companies for the business being conducted and properties owned or leased by the Company, and the Company reasonably believes such insurance coverage to
be adequate against all liabilities, claims and risks against which it is customary for comparably situated companies to insure. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.19.
<U>Compliance with Nasdaq Continued Listing Requirements</U>. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company&#146;s Knowledge, threatened against the Company
relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company&#146;s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.20. <U>Brokers and Finders</U>. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid
right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of the Company. No Investor shall have any
obligation with respect to any fees, or with respect to any claims made by or on behalf of other Persons for fees, in each case of the type contemplated by this Section&nbsp;4.20 that may be due in connection with the transactions contemplated by
this Agreement or the Transaction Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.21. <U>No Integrated Offering</U>. Assuming the accuracy of the Investors&#146;
representations and warranties set forth in Section&nbsp;5, neither the Company, nor any of its Affiliates, nor any Person acting on its or their behalf has, directly or indirectly, made any offers or sales of any security or solicited any offers to
buy any security, under circumstances that would cause this offering of the Securities to be integrated with prior offerings by the Company for purposes of any applicable shareholder approval provisions of any Trading Market on which any of the
securities of the Company are listed or designated. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.22. Intentionally Omitted. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.23. <U>Questionable Payments</U>. Neither the Company nor, to the Company&#146;s
Knowledge, any of its current or former directors, officers, employees, agents or other Persons acting on behalf of the Company, has on behalf of the Company in connection with its business: (a)&nbsp;used any corporate funds for unlawful
contributions, gifts, entertainment or other unlawful expenses relating to political activity; (b)&nbsp;made any direct or indirect unlawful payments to any governmental officials or employees from corporate funds; (c)&nbsp;established or maintained
any unlawful or unrecorded fund of corporate monies or other assets which is in violation of law; (d)&nbsp;made any false or fictitious entries on the books and records of the Company; or (e)&nbsp;made any unlawful bribe, rebate, payoff, influence
payment, kickback or other unlawful payment of any nature. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.24. <U>Transactions with Affiliates</U>. None of the executive officers or
directors of the Company and, to the Company&#146;s Knowledge, none of the employees of the Company is presently a party to any transaction with the Company (other than as holders of stock options, restricted stock units, warrants and/or restricted
stock, and for services as employees, officers and directors), including any contract, agreement or other arrangement providing for the furnishing of services to or by, providing for rental of real or personal property to or from, or otherwise
requiring payments to or from any officer, director or such employee or, to the Company&#146;s Knowledge, any entity in which any officer, director, or any such employee has a substantial interest or is an officer, director, trustee or partner. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.25. <U>Internal Controls</U>. The Company has established and maintains disclosure controls and procedures (as defined in Rules <FONT
STYLE="white-space:nowrap">13a-15</FONT> and <FONT STYLE="white-space:nowrap">15d-15</FONT> under the 1934 Act), which are designed to ensure that material information relating to the Company is made known to the Company&#146;s principal executive
officer and its principal financial officer by others within those entities. Since the end of the Company&#146;s most recent audited fiscal year, there have been no material weaknesses in the Company&#146;s internal control over financial reporting
(whether or not remediated) and no change in the Company&#146;s internal control over financial reporting that has materially affected, or would reasonably be expected to materially affect, the Company&#146;s internal control over financial
reporting. The Company is not aware of any change in its internal controls over financial reporting that has occurred during its most recent fiscal quarter that has materially affected, or would reasonably be expected to materially affect, the
Company&#146;s internal control over financial reporting. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.26. <U>Disclosures</U>. Neither the Company nor any Person acting on its
behalf has provided the Investors or their agents or counsel with any information that constitutes or would reasonably be expected to constitute material nonpublic information concerning the Company, other than with respect to the transactions
contemplated hereby. The SEC Filings do not contain any untrue statement of a material fact or omit to state a material fact necessary in order to make the statements contained therein, in light of the circumstances under which they were made, not
misleading. The Company understands and confirms that the Investors will rely on the foregoing representations in effecting transactions in securities of the Company.</P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.27. <U>Required Filings</U>. Except for the transactions contemplated by this Agreement, including the acquisition of the Placement
Securities contemplated hereby, no event or circumstance has occurred or information exists with respect to the Company or its business, properties, operations or financial condition, which, under applicable law, rule or regulation, requires public
disclosure or announcement by the Company but which has not been so publicly announced or disclosed (assuming for this purpose that the SEC Filings are being incorporated by reference into an effective registration statement filed by the Company
under the 1933 Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.28. <U>Investment Company</U>. The Company is not required to be registered as, and immediately following the
Closing will not be required to register as, an &#147;investment company&#148; within the meaning of the Investment Company Act of 1940, as amended. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.29. <U>Tests and Preclinical and Clinical Trials</U>. (i)&nbsp;The preclinical studies and
clinical trials conducted by or, to the Company&#146;s Knowledge, on behalf of or sponsored by the Company, or in which the Company has participated, that are described in the SEC Filings, or the results of which are referred to in the SEC Filings,
as applicable, were, and if still pending are, being conducted in all material respects in accordance with standard medical and scientific research standards and procedures for products or product candidates comparable to those being developed by
the Company and all applicable statutes and all applicable rules and regulations of the U.S. Food and Drug Administration and comparable regulatory agencies outside of the United States to which they are subject, including the European Medicines
Agency (collectively, the &#147;<U>Regulatory Authorities</U>&#148;) and Good Clinical Practice and Good Laboratory Practice requirements; (ii)&nbsp;the descriptions in the SEC Filings of the results of such studies and trials are accurate and
complete descriptions in all material respects and fairly present the data derived therefrom; (iii)&nbsp;to the Company&#146;s Knowledge, there are no other studies or trials not described in the SEC Filings, the results of which the Company
believes are inconsistent with or reasonably call into question the results described or referred to in the SEC Filings; (iv)&nbsp;the Company has operated at all times and are currently in compliance with all applicable statutes, rules and
regulations of the Regulatory Authorities, except where such <FONT STYLE="white-space:nowrap">non-compliance</FONT> would not, individually or in the aggregate, have a Material Adverse Effect; and (v)&nbsp;the Company has not received any written
notices, correspondence or other communications from the Regulatory Authorities or any other governmental agency requiring or threatening the termination, material modification or suspension of any preclinical studies or clinical trials that are
described in the SEC Filings or the results of which are referred to in the SEC Filings, other than ordinary course communications with respect to modifications in connection with the design and implementation of such studies or trials, and, to the
Company&#146;s Knowledge, there are no reasonable grounds for the same. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.30. <U>Manipulation of Price</U>.&nbsp;The Company has not
taken, and, to the Company&#146;s Knowledge, no Person acting on its behalf has taken, directly or indirectly, any action designed to cause or to result in the stabilization or manipulation of the price of any security of the Company to facilitate
the sale or resale of any of the Securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.31. <U>Anti-Bribery and Anti-Money Laundering Laws</U>. Each of the Company, and its
officers, directors, supervisors, managers, agents, or employees are and have at all times been in compliance with and their participation in the offering will not violate: (A)&nbsp;anti-bribery laws, including but not limited to, any applicable
law, rule, or regulation of any locality, including but not limited to any law, rule, or regulation promulgated to implement the OECD Convention on Combating Bribery of Foreign Public Officials in International Business Transactions, signed
December&nbsp;17, 1997, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.K. Bribery Act 2010, or any other law, rule or regulation of similar purposes and scope or (B)&nbsp;anti-money laundering laws, including, but not
limited to, applicable federal, state, international, foreign or other laws, regulations or government guidance regarding anti-money laundering, including, without limitation, Title 18 US. Code sections 1956 and 1957, the Patriot Act, the Bank
Secrecy Act, and international anti-money laundering principles or procedures by an intergovernmental group or organization, such as the Financial Action Task Force on Money Laundering, of which the United States is a member and with which
designation the United States representative to the group or organization continues to concur, all as amended, and any Executive order, directive, or regulation pursuant to the authority of any of the foregoing, or any orders or licenses issued
thereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.32. Intentionally Omitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.33. <U>No Additional Agreements</U>. The Company has no other agreements or understandings (including, without limitation, side letters)
with any Investor to purchase Placement Securities on terms more favorable to such Investor than as set forth herein. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">4.34. <U>Shell Company Status</U>. The Company is not, and has never been, an issuer
identified in Rule 144(i)(1). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">5. <U>Representations and Warranties of the Investors</U>. Each of the Investors hereby severally, and not
jointly, represents and warrants to the Company that: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.1. <U>Organization and Existence</U>. Such Investor is a duly incorporated or
organized and validly existing corporation, limited partnership, limited liability company or other legal entity, has all requisite corporate, partnership or limited liability company power and authority to enter into and consummate the transactions
contemplated by the Transaction Documents to which such Investor is a party and to carry out its obligations hereunder and thereunder, and to invest in the Securities pursuant to this Agreement, and is in good standing under the laws of the
jurisdiction of its incorporation or organization. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.2. <U>Authorization</U>. The execution, delivery and performance by such Investor of
the Transaction Documents to which such Investor is a party have been duly authorized and each has been duly executed and when delivered will constitute the valid and legally binding obligation of such Investor, enforceable against such Investor in
accordance with their respective terms, subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability, relating to or affecting creditors&#146; rights generally, and general principles
of equity. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.3. <U>Purchase Entirely for Own Account</U>. The Securities to be received by such Investor hereunder will be acquired for
such Investor&#146;s own account, not as nominee or agent, for the purpose of investment and not with a view to the resale or distribution of any part thereof in violation of the 1933 Act, and such Investor has no present intention of selling,
granting any participation in, or otherwise distributing the same in violation of the 1933 Act without prejudice, however, to such Investor&#146;s right at all times to sell or otherwise dispose of all or any part of such Securities in compliance
with applicable federal and state securities laws (this representation and warranty not limiting such Investor&#146;s right to sell the Securities pursuant to the Registration Statement or otherwise in compliance with applicable federal and state
securities laws). The Placement Securities are being purchased by such Investor in the ordinary course of its business. Nothing contained herein shall be deemed a representation or warranty by such Investor to hold the Securities for any period of
time. Such Investor is not a broker-dealer registered with the SEC under the 1934 Act or an entity engaged in a business that would require it to be so registered. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.4. <U>Investment Experience</U>. Such Investor acknowledges that it can bear the economic risk and complete loss of its investment in the
Securities and has such knowledge and experience in financial or business matters that it is capable of evaluating the merits and risks of the investment contemplated hereby. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.5. <U>Disclosure of Information</U>. Such Investor has had an opportunity to receive, review and understand all information related to the
Company requested by it and to ask questions of and receive answers from the Company regarding the Company, its business and the terms and conditions of the offering of the Securities, and has conducted and completed its own independent due
diligence. Such Investor acknowledges that copies of the SEC Filings are available on the EDGAR system. Based on the information such Investor has deemed appropriate, it has independently made its own analysis and decision to enter into the
Transaction Documents to which such Investor is a party. Such Investor is relying exclusively on its own investment analysis and due diligence (including professional advice it deems appropriate) with respect to the execution, delivery and
performance of the Transaction Documents to which such Investor is a party, the Securities and the business, condition (financial and otherwise), management, operations, properties and prospects of the Company, including but not limited to all
business, legal, regulatory, accounting, credit and tax matters. Neither such inquiries nor any other due diligence investigation conducted by such Investor shall modify, limit or otherwise affect such Investor&#146;s right to rely on the
Company&#146;s representations and warranties contained in this Agreement. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.6. <U>Accredited Investor</U>. Such Investor is an &#147;accredited investor&#148; within
the meaning of Rule 501(a) of Regulation D. Such investor is a sophisticated institutional investor with sufficient knowledge and experience in investing in private equity transactions to properly evaluate the risks and merits of its purchase of the
Securities. Such Investor has determined based on its own independent review and such professional advice as it deems appropriate that its purchase of the Securities and participation in the transactions contemplated by the Transaction Documents
(i)&nbsp;are fully consistent with its financial needs, objectives and condition, (ii)&nbsp;comply and are fully consistent with all investment policies, guidelines and other restrictions applicable to such Investor, (iii)&nbsp;have been duly
authorized and approved by all necessary action, (iv)&nbsp;do not and will not violate or constitute a default under such Investor&#146;s charter, bylaws or other constituent document or under any law, rule, regulation, agreement or other obligation
by which such Investor is bound and (v)&nbsp;are a fit, proper and suitable investment for such Investor, notwithstanding the substantial risks inherent in investing in or holding the Securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.7. Intentionally Omitted. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.8. <U>Brokers and Finders</U>. No Person will have, as a result of the transactions contemplated by the Transaction Documents, any valid
right, interest or claim against or upon the Company or an Investor for any commission, fee or other compensation pursuant to any agreement, arrangement or understanding entered into by or on behalf of such Investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.9. <U>Short Sales and Confidentiality Prior to the Date Hereof</U>. Other than consummating the transactions contemplated hereunder, such
Investor has not, nor has any Person acting on behalf of or pursuant to any understanding with such Investor, directly or indirectly executed any purchases or sales, including Short Sales,&nbsp;of the securities of the Company during the period
commencing as of the time that such Investor first communicated with the Company regarding the transactions contemplated hereby and ending immediately prior to the date hereof.&nbsp;Notwithstanding the foregoing, in the case of an Investor that is a
multi-managed investment vehicle whereby separate portfolio managers manage separate portions of such Investor&#146;s assets and the portfolio managers have no direct knowledge of the investment decisions made by the portfolio managers managing
other portions of such Investor&#146;s assets, the representation set forth above shall only apply with respect to the portion of assets managed by the portfolio manager that made the investment decision to purchase the Securities covered by this
Agreement.&nbsp;Other than to other Persons party to this Agreement and other than to such Person&#146;s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit evaluation of the investment, and the
performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law, such Investor has maintained the confidentiality of all disclosures made to it in connection
with this transaction (including the existence and terms of this transaction). Notwithstanding the foregoing, for avoidance of doubt, nothing contained herein shall constitute a representation or warranty, or preclude any actions, with respect to
the identification of the availability of, or securing of, available shares to borrow in order to effect Short Sales or similar transactions in the future. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.10. <U>No Government Recommendation or Approval</U>. Such Investor understands that no United States federal or state agency, or similar
agency of any other country, has reviewed, approved, passed upon, or made any recommendation or endorsement of the Company or the purchase of the Securities. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.11. <U>No Intent to Effect a Change of Control</U>. Such Investor has no present intent to
effect a &#147;change of control&#148; of the Company as such term is understood under the rules promulgated pursuant to Section&nbsp;13(d) of the 1934 Act. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.12. <U>Residency</U>. Such Investor&#146;s office in which its investment decision with respect to the Securities was made is located at the
address immediately below such Investor&#146;s name on its signature page hereto. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">5.13. <U>No Conflicts</U>. The execution, delivery and
performance by such Investor of the Transaction Documents to which such Investor is a party and the consummation by such Investor of the transactions contemplated hereby and thereby will not (i)&nbsp;result in a violation of the organizational
documents of such Investor or (ii)&nbsp;conflict with, or constitute a default (or an event which with notice or lapse of time or both would become a default) under, or give to others any rights of termination, amendment, acceleration or
cancellation of, any agreement, indenture or instrument to which such Investor is a party, or (iii)&nbsp;result in a violation of any law, rule, regulation, order, judgment or decree (including federal and state securities laws) applicable to such
Investor, except in the case of clauses (ii)&nbsp;and (iii) above, for such conflicts, defaults, rights or violations which would not, individually or in the aggregate, reasonably be expected to have a material adverse effect on the ability of such
Investor to perform its obligations hereunder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">6. <U>Conditions to Closing</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.1. <U>Conditions to the Investors&#146; Obligations</U>. The obligation of each Investor to purchase Placement Securities at the Closing is
subject to the fulfillment to such Investor&#146;s satisfaction, on or prior to the Closing Date, of the following conditions, any of which may be waived by such Investor (as to itself only): </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The representations and warranties made by the Company in Section&nbsp;4 hereof shall be true and correct in all material respects as of
the date hereof and as of the Closing Date, as though made on and as of such date, except to the extent any such representation or warranty expressly speaks as of an earlier date, in which case such representation or warranty shall be true and
correct in all material respects as of such earlier date. The Company shall have performed in all material respects all obligations and covenants herein required to be performed by it on or prior to the Closing Date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) The Company shall have obtained any and all consents, permits, approvals, registrations and waivers necessary for the consummation of the
purchase and sale of the Placement Securities and the consummation of the other transactions contemplated by the Transaction Documents, all of which shall be in full force and effect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(c) The Company shall have filed with Nasdaq a Listing of Additional Shares notice form for the listing of the Warrant Shares. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(d) No judgment, writ, order, injunction, award or decree of or by any court, or judge, justice or magistrate, including any bankruptcy court
or judge, or any order of or by any governmental authority, shall have been issued, and no action or proceeding shall have been instituted by any governmental authority, enjoining or preventing the consummation of the transactions contemplated
hereby or in the other Transaction Documents. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(e) The Company shall have delivered a Certificate, executed on behalf of the Company by
its Chief Executive Officer or its Chief Financial Officer, dated as of the Closing Date, certifying to the fulfillment of the conditions specified in subsections (a), (b), (c), (d) and (i)&nbsp;of this Section&nbsp;6.1. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(f) The Company shall have delivered a Certificate, executed on behalf of the Company by its
Secretary, dated as of the Closing Date, certifying the resolutions adopted by the Board of Directors of the Company approving the transactions contemplated by this Agreement, the other Transaction Documents and the issuance of the Placement
Securities, certifying the current versions of the Certificate of Incorporation and Bylaws of the Company and certifying as to the signatures and authority of persons signing the Transaction Documents and related documents on behalf of the Company.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(g) There shall have been no Material Adverse Effect with respect to the Company since the date hereof. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(h) The Company shall have delivered the Prospectus and Prospectus Supplement (which may be delivered in accordance with Rule 172 under the
1933 Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(i) No stop order or suspension of trading shall have been imposed by Nasdaq, the SEC or any other governmental or regulatory
body with respect to public trading in the Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.2. <U>Conditions to Obligations of the Company</U>. The Company&#146;s
obligation to sell and issue the Placement Securities at the Closing is subject to the fulfillment to the satisfaction of the Company on or prior to the Closing Date of the following conditions, any of which may be waived by the Company: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The representations and warranties made by the Investors in Section&nbsp;5 hereof shall be true and correct as of the date hereof, and
shall be true and correct as of the Closing Date with the same force and effect as if they had been made on and as of such date. The Investors shall have performed in all material respects all obligations and covenants herein required to be
performed by them on or prior to the Closing Date. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b) Any Investor purchasing Placement Securities at the Closing shall have paid in
full its purchase price to the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">6.3. <U>Termination of Obligations to Effect Closing; Effects</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(a) The obligations of the Company, on the one hand, and the Investors, on the other hand, to effect the Closing shall terminate as follows:
</P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(i) Upon the mutual written consent of the Company and Investors that agreed to purchase a majority of the Placement Securities to be
issued and sold pursuant to this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(ii) By the Company if any of the conditions set forth in Section&nbsp;6.2 shall have become
incapable of fulfillment, and shall not have been waived by the Company; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iii) By an Investor (with respect to itself only) if any of
the conditions set forth in Section&nbsp;6.1 shall have become incapable of fulfillment, and shall not have been waived by the Investor; or </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:13%; font-size:10pt; font-family:Times New Roman">(iv) By either the Company or any Investor (with respect to itself only) if the Closing has
not occurred on or prior to the third Trading Day following the date of this Agreement; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">provided, however, that, except in the case of clause
(i)&nbsp;above, the party seeking to terminate its obligation to effect the Closing shall not then be in breach of any of its representations, warranties, covenants or agreements contained in this Agreement or the other Transaction Documents if such
breach has resulted in the circumstances giving rise to such party&#146;s seeking to terminate its obligation to effect the Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">(b)
In the event of termination by the Company or any Investor of its obligations to effect the Closing pursuant to this Section&nbsp;6.3, written notice thereof shall be given to the other Investors by the Company and the other Investors shall have the
right to terminate their obligations to effect the Closing upon written notice to the Company and the other Investors. Nothing in this Section&nbsp;6.3 shall be deemed to release any party from any liability for any breach by such party of the terms
and provisions of this Agreement or the other Transaction Documents or to impair the right of any party to compel specific performance by any other party of its obligations under this Agreement or the other Transaction Documents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">7. <U>Covenants and Agreements of the Company</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.1. <U>Furnishing of Information</U>. Until the time that no Investor owns Securities, the Company covenants to timely file (or obtain
extensions in respect thereof and file within the applicable grace period) all reports required to be filed by the Company after the date hereof pursuant to the 1934 Act, provided that the Company is then subject to the reporting requirements of the
1934 Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.2. <U>Short Sales and Confidentiality After the Date Hereof</U>. Each Investor covenants that neither it nor any Affiliates
acting on its behalf or pursuant to any understanding with it will trade in the securities of the Company or execute any Short Sales during the period from the date hereof until the earlier of such time as (i)&nbsp;the transactions contemplated by
this Agreement are first publicly announced or (ii)&nbsp;this Agreement is terminated in full. Each Investor covenants that until such time as the transactions contemplated by this Agreement are publicly disclosed by the Company, such Investor and
its Affiliates will maintain the confidentiality of the existence and terms of this Agreement, other than, in each case, to such Person&#146;s outside attorney, accountant, auditor or investment advisor only to the extent necessary to permit
evaluation of the investment, and the performance of the necessary or required tax, accounting, financial, legal, or administrative tasks and services and other than as may be required by law. Each Investor understands and acknowledges that the SEC
currently takes the position that coverage of Short Sales of shares of the Common Stock &#147;against the box&#148; prior to effectiveness of a resale registration statement with securities included in such registration statement would be a
violation of Section&nbsp;5 of the 1933 Act, as set forth in Item 239.10 of the Securities Act Sections Compliance and Disclosure Interpretations compiled by the Office of Chief Counsel, Division of Corporation Finance. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">7.3. <U>Nasdaq Listing</U>. The Company will use commercially reasonable efforts to continue the listing and trading of its Common Stock on
Nasdaq and, in accordance therewith, will use commercially reasonable efforts to comply in all material respects with the Company&#146;s reporting, filing and other obligations under the bylaws or rules of such market or exchange, as applicable.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">8. <U>Survival and Indemnification</U>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.1. <U>Survival</U>. The representations, warranties, covenants and agreements contained in this Agreement shall survive the Closing of the
transactions contemplated by this Agreement for the applicable statute of limitations. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.2. <U>Indemnification</U>. The Company agrees to indemnify and hold harmless each Investor
and its Affiliates, and their respective directors, officers, trustees, members, managers, employees, investment advisers and agents, from and against any and all losses, claims, damages, liabilities and expenses (including without limitation
reasonable and documented attorney fees and disbursements and other documented <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> expenses reasonably incurred in connection with investigating, preparing or
defending any action, claim or proceeding, pending or threatened and the costs of enforcement thereof) to which such Person may become subject as a result of any breach of representation, warranty, covenant or agreement made by or to be performed on
the part of the Company under the Transaction Documents, and will reimburse any such Person for all such amounts as they are incurred by such Person solely to the extent such amounts have been finally judicially determined not to have resulted from
such Person&#146;s fraud or willful misconduct. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">8.3. <U>Conduct of Indemnification Proceedings</U><B><I>. </I></B>Any person entitled to
indemnification hereunder shall (i)&nbsp;give prompt written notice to the indemnifying party of any claim with respect to which it seeks indemnification and (ii)&nbsp;permit such indemnifying party to assume the defense of such claim with counsel
reasonably satisfactory to the indemnified party; provided that any person entitled to indemnification hereunder shall have the right to employ separate counsel and to participate in the defense of such claim, but the fees and expenses of such
counsel shall be at the expense of such person unless (a)&nbsp;the indemnifying party has agreed in writing to pay such fees or expenses, (b)&nbsp;the indemnifying party shall have failed to assume the defense of such claim and employ counsel
reasonably satisfactory to such person or (c)&nbsp;in the reasonable judgment of any such person, based upon written advice of its counsel, a conflict of interest exists between such person and the indemnifying party with respect to such claims (in
which case, if the person notifies the indemnifying party in writing that such person elects to employ separate counsel at the expense of the indemnifying party, the indemnifying party shall not have the right to assume the defense of such claim on
behalf of such person); and provided, further, that the failure of any indemnified party to give written notice as provided herein shall not relieve the indemnifying party of its obligations hereunder, except to the extent that such failure to give
notice shall materially adversely affect the indemnifying party in the defense of any such claim or litigation. It is understood that the indemnifying party shall not, in connection with any proceeding in the same jurisdiction, be liable for fees or
expenses of more than one separate firm of attorneys at any time for all such indemnified parties. No indemnifying party will, except with the consent of the indemnified party, which consent shall not be unreasonably withheld, conditioned or
delayed, consent to entry of any judgment or enter into any settlement that does not include as an unconditional term thereof the giving by the claimant or plaintiff to such indemnified party of a release from all liability in respect of such claim
or litigation. No indemnified party will, except with the consent of the indemnifying party, which consent shall not be unreasonably withheld, conditioned or delayed, consent to entry of any judgment or enter into any settlement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">9. <U>Miscellaneous</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.1.
<U>Successors and Assigns</U>. This Agreement may not be assigned by a party hereto without the prior written consent of the Company or each of the Investors, as applicable, provided, however, that an Investor may assign its rights and delegate its
duties hereunder in whole or in part to an Affiliate or to a third party acquiring some or all of its Securities in a transaction complying with applicable securities laws without the prior written consent of the Company or the other Investors,
provided such assignee agrees in writing to be bound by the provisions hereof that apply to Investors. The provisions of this Agreement shall inure to the benefit of and be binding upon the respective permitted successors and assigns of the parties.
Without limiting the generality of the foregoing, in the event that the Company is a party to a merger, consolidation, share exchange or similar business combination transaction in which the Common Stock is converted into the equity securities of
another Person, from and after the effective time of such transaction, such Person shall, by virtue of such </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
transaction, be deemed to have assumed the obligations of the Company hereunder, the term &#147;Company&#148; shall be deemed to refer to such Person and the term &#147;Securities&#148; shall be
deemed to refer to the securities received by the Investors in connection with such transaction. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective permitted
successors and assigns any rights, remedies, obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.2. <U>Counterparts</U>. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of
which together shall constitute one and the same instrument. Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signatures complying with the U.S. federal ESIGN Act of 2000, e.g., www.docusign.com) or other
transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.3. <U>Titles and Subtitles</U>. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered
in construing or interpreting this Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.4. <U>Notices</U>. Unless otherwise provided, any notice required or permitted under this
Agreement shall be given in writing and shall be deemed effectively given as hereinafter described (i)&nbsp;if given by personal delivery, then such notice shall be deemed given upon such delivery, (ii)&nbsp;if given by facsimile or <FONT
STYLE="white-space:nowrap">e-mail,</FONT> then such notice shall be deemed given upon receipt of confirmation of complete facsimile transmittal or confirmation of receipt of an <FONT STYLE="white-space:nowrap">e-mail</FONT> transmission,
(iii)&nbsp;if given by mail, then such notice shall be deemed given upon the earlier of (A)&nbsp;receipt of such notice by the recipient or (B)&nbsp;three (3) days after such notice is deposited in first class mail, postage prepaid, and (iv)&nbsp;if
given by an internationally recognized overnight air courier, then such notice shall be deemed given one (1)&nbsp;Business Day after delivery to such carrier. All notices shall be addressed to the party to be notified at the address as follows, or
at such other address as such party may designate by ten (10)&nbsp;days&#146; advance written notice to the other party: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If to the
Company: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Monte Rosa Therapeutics, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">321 Harrison Avenue, Suite 900 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Boston, MA 02118 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Phil
Nickson </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">E-mail:</FONT> pnickson@monterosatx.com </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">With a copy (which will not constitute notice) to: </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Goodwin Procter LLP </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">100 Northern
Avenue </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Boston, MA 02210 </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Attention: Robert E. Puopolo </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:9%; font-size:10pt; font-family:Times New Roman">Email: RPuopolo@goodwinlaw.com </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">If to the
Investors: </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:13%; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only to the addresses set forth on the signature pages hereto. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.5. <U>Expenses</U>. The parties hereto shall pay their own costs and expenses in
connection herewith regardless of whether the transactions contemplated hereby are consummated, except that the Company has agreed to reimburse the Investors in an aggregate amount of up to $100,000 for Investors&#146; reasonable and documented
legal fees at the time of Closing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.6. <U>Amendments and Waivers</U>. Prior to Closing, no amendment or waiver of any provision of this
Agreement will be effective with respect to any party unless made in writing and signed by a duly authorized representative of such party. Following the Closing, any term of this Agreement may be amended and the observance of any term of this
Agreement may be waived (either generally or in a particular instance and either retroactively or prospectively), only with the written consent of the Company and the Investors. Notwithstanding the foregoing, this Agreement may not be amended and
the observance of any term of this Agreement may not be waived with respect to any Investor without the written consent of such Investor unless such amendment or waiver applies to all Investors in the same fashion. Any amendment or waiver effected
in accordance with this paragraph shall be binding upon (i)&nbsp;prior to Closing, each Investor that signed such amendment or waiver and (ii)&nbsp;following the Closing, each holder of any Securities purchased under this Agreement at the time
outstanding, and in each case, each future holder of all such Securities and the Company. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.7. <U>Publicity</U>. Except as set forth
below, no public release or announcement concerning the transactions contemplated hereby shall be issued by the Investors without the prior consent of the Company, except as such release or announcement may be required by law or the applicable rules
or regulations of any securities exchange or securities market, in which case the Investors shall allow the Company reasonable time to comment on such release or announcement in advance of such issuance. Notwithstanding the foregoing, each Investor
may identify the Company and the value of such Investor&#146;s security holdings in the Company in accordance with applicable investment reporting and disclosure regulations or internal policies without prior notice to or consent from the Company
(including, for the avoidance of doubt, filings pursuant to Sections 13 and 16 of the 1934 Act). The Company shall not include the name of any Investor or any Affiliate or investment adviser of such Investor in any press release or public
announcement (which, for the avoidance of doubt, shall not include any SEC Filing to the extent such disclosure is required by SEC rules and regulations) without the prior written consent of such Investor. In addition, the Company will make such
other filings and notices in the manner and time required by the SEC or Nasdaq. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.8. <U>Severability</U>. Any provision of this Agreement
that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to the extent of such prohibition or unenforceability without invalidating the remaining provisions hereof but shall be interpreted as if it were
written so as to be enforceable to the maximum extent permitted by applicable law, and any such prohibition or unenforceability in any jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. To the extent
permitted by applicable law, the parties hereby waive any provision of law which renders any provision hereof prohibited or unenforceable in any respect. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.9. <U>Entire Agreement</U>. This Agreement, including the signature pages and Exhibits, and the other Transaction Documents between the
Company and each Investor constitute the entire agreement among the parties hereof with respect to the subject matter hereof and thereof and supersede all prior agreements and understandings, both oral and written, between the parties with respect
to the subject matter hereof and thereof. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.10. <U>Further Assurances</U>. The parties shall execute and deliver all such further
instruments and documents and take all such other actions as may reasonably be required to carry out the transactions contemplated hereby and to evidence the fulfillment of the agreements herein contained. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.11. <U>Governing Law</U>. This Agreement shall be governed by, and construed in accordance
with, the laws of the State of New York. Service of process in connection with any such suit, action or proceeding may be served on each party hereto anywhere in the world by the same methods as are specified for the giving of notices under this
Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:9%; font-size:10pt; font-family:Times New Roman">9.12. <U>Independent Nature of Investors&#146; Obligations and Rights</U>. The obligations of each Investor under any
Transaction Document are several and not joint with the obligations of any other Investor, and no Investor shall be responsible in any way for the performance of the obligations of any other Investor under any Transaction Document. The decision of
each Investor to purchase Placement Securities pursuant to the Transaction Documents has been made by such Investor independently of any other Investor. Nothing contained herein or in any Transaction Document, and no action taken by any Investor
pursuant thereto, shall be deemed to constitute the Investors as a partnership, an association, a joint venture or any other kind of entity, or create a presumption that the Investors are in any way acting in concert or as a group with respect to
such obligations or the transactions contemplated by the Transaction Documents. Each Investor acknowledges that no other Investor has acted as agent for such Investor in connection with making its investment hereunder and that no Investor will be
acting as agent of such Investor in connection with monitoring its investment in the Securities or enforcing its rights under the Transaction Documents. Each Investor shall be entitled to independently protect and enforce its rights, including,
without limitation, the rights arising out of this Agreement or out of the other Transaction Documents, and it shall not be necessary for any other Investor to be joined as an additional party in any proceeding for such purpose. The Company
acknowledges that each of the Investors has been provided with the same Transaction Documents for the purpose of closing a transaction with multiple Investors and not because it was required or requested to do so by any Investor. It is expressly
understood and agreed that each provision contained in this Agreement is between the Company and an Investor, solely, and not between the Company and the Investors collectively and not between and among the Investors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">[remainder of page intentionally left blank] </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized
officers to execute this Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="45%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>

<TD VALIGN="bottom"></TD>
<TD WIDTH="3%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="45%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">COMPANY:</P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" COLSPAN="3"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">MONTE ROSA THERAPEUTICS, INC.</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">By:</P></TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">/s/ Markus Warmuth</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Name: Markus Warmuth, M.D.</P></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Title: Chief Executive Officer</P></TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties have executed this Agreement or caused their duly authorized
officers to execute this Agreement as of the date first above written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>

<TD WIDTH="7%"></TD>

<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="92%"></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3"><U>INVESTOR</U></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">By:</TD>
<TD VALIGN="bottom" STYLE=" BORDER-BOTTOM:1px solid #000000">&nbsp;</TD>
<TD VALIGN="top" STYLE="BORDER-BOTTOM:1px solid #000000">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Name:</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="3">Title:</TD></TR>
</TABLE>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT A </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Schedule of Investors </B></P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXHIBIT B </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Form of <FONT STYLE="white-space:nowrap">Pre-Funded</FONT> Warrant </B></P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>5
<FILENAME>d512767dex991.htm
<DESCRIPTION>EX-99.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-99.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE" STYLE="line-height:Normal">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 99.1 </B></P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g512767g1026185919418.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Monte Rosa Therapeutics Announces $25 Million Registered Direct Offering, Priced <FONT
STYLE="white-space:nowrap">At-</FONT> <FONT STYLE="white-space:nowrap">the-Market</FONT> Under Nasdaq Rules </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>BOSTON, Mass.,
October</B><B></B><B>&nbsp;26, 2023 </B>&#150; <U>Monte Rosa Therapeutics, Inc.</U> (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that it has raised
$25&nbsp;million <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">at-the-market</FONT></FONT> from a life sciences-dedicated investor. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The company has entered into a definitive agreement for the issuance and sale of <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants to purchase
10,000,400 shares of its common stock at an offering price of $2.4999 per <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant, which represents the closing price for the common stock on October
25<SUP STYLE="font-size:75%; vertical-align:top">th</SUP> less the $0.0001 per share exercise price for each <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrant. The <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants will be
immediately excercisable at a nominal exercise price of $0.0001 per share and may be exercised at any time until the <FONT STYLE="white-space:nowrap">pre-funded</FONT> warrants are exercised in full. The closing of the offering is expected to occur
on or about October&nbsp;30, 2023, subject to the satisfaction of customary closing conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The gross proceeds to Monte Rosa from this offering are
expected to be approximately $25&nbsp;million, before deducting certain offering expenses. Monte Rosa intends to use the net proceeds from the offering towards its further advancement of its clinical and late preclinical pipeline, including <FONT
STYLE="white-space:nowrap">MRT-2359,</FONT> its orally bioavailable, GSPT1-directed MGD, <FONT STYLE="white-space:nowrap">MRT-6160,</FONT> its orally bioavailable VAV1-directed MGD, and its NEK7 program, to key value inflection points. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The securities above are being offering pursuant to a shelf registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> <FONT
STYLE="white-space:nowrap">(333-266003)</FONT> that was filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on July&nbsp;1, 2022, and was declared effective by the SEC on July&nbsp;13, 2022. The offering is being made only by
means of the written prospectus and prospectus supplement that form a part of the registration statement. A prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and will be available on the SEC&#146;s
website at <U>www.sec.gov</U>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>This press release does not constitute an offer to sell or the solicitation of offers to buy any of the securities
being offered, and shall not constitute an offer, solicitation or sale of any security in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any
such state or jurisdiction. </I></P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>About Monte Rosa </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Monte Rosa Therapeutics is a clinical-stage biotechnology company developing highly selective molecular glue degrader (MGD) medicines for patients living with
serious diseases in the areas of oncology, autoimmune and inflammatory diseases, and more. MGDs are small molecule protein degraders that have the potential to treat many diseases that other modalities, including other degraders, cannot. Monta
Rosa&#146;s QuEEN<SUP STYLE="font-size:75%; vertical-align:top">&#153;</SUP> (Quantitative and Engineered Elimination of Neosubstrates) discovery engine combines AI-guided chemistry, diverse chemical libraries, structural biology and proteomics to
identify degradable protein targets and rationally design MGDs with unprecedented selectivity. The QuEEN discovery engine enables access to a wide-ranging and differentiated target space of well-validated biology across multiple therapeutic areas.
Monte Rosa has developed the industry&#146;s leading pipeline of MGDs, which spans oncology, autoimmune and inflammatory disease and beyond. For more information, visit <U>www.monterosatx.com</U>. </P>
</DIV></Center>


<p style="margin-top:1em; margin-bottom:0em; page-break-before:always"> </p>
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">

 <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g512767g1026185919418.jpg" ALT="LOGO">
 </P> <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Forward-Looking Statements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This communication includes express and implied &#147;forward-looking statements,&#148; including forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and in some cases, can be identified by terms such as &#147;may,&#148; &#147;might,&#148; &#147;will,&#148; &#147;could,&#148;
&#147;would,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;plan,&#148; &#147;objective,&#148; &#147;anticipate,&#148; &#147;believe,&#148; &#147;estimate,&#148; &#147;predict,&#148; &#147;potential,&#148;
&#147;continue,&#148; &#147;ongoing,&#148; or the negative of these terms, or other comparable terminology intended to identify statements about the future. Forward-looking statements contained herein include, but are not limited to, the expected
closing of the offering and the Company&#146;s anticipated uses of capital to further advance its clinical and late preclinical pipeline, including <FONT STYLE="white-space:nowrap">MRT-2359,</FONT> <FONT STYLE="white-space:nowrap">MRT-6160,</FONT>
and its NEK7 program, to key value inflection points. By their nature, these statements are subject to numerous risks and uncertainties, including those risks and uncertainties set forth in our most recent Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2022, filed with the U.S. Securities and Exchange Commission on March&nbsp;16, 2023, and any subsequent filings, that could cause actual results, performance or achievement
to differ materially and adversely from those anticipated or implied in the statements. You should not rely upon forward-looking statements as predictions of future events. Although our management believes that the expectations reflected in our
statements are reasonable, we cannot guarantee that the future results, performance, or events and circumstances described in the forward-looking statements will be achieved or occur. Recipients are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date such statements are made and should not be construed as statements of fact. We undertake no obligation to publicly update any forward-looking statements, whether as a result of new
information, any future presentations, or otherwise, except as required by applicable law. Certain information contained in these materials and any statements made orally during any presentation of these materials that relate to the materials or are
based on studies, publications, surveys and other data obtained from third-party sources and our own internal estimates and research. While we believe these third-party studies, publications, surveys and other data to be reliable as of the date of
these materials, we have not independently verified, and make no representations as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, no independent source has evaluated the
reasonableness or accuracy of our internal estimates or research and no reliance should be made on any information or statements made in these materials relating to or based on such internal estimates and research. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Investors </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Andrew Funderburk, Kendall IR </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>afunderburk@kendallir.com </U></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Media </B> </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cory Tromblee, Scient PR </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><U>media@monterosatx.com</U> </P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>glue-20231026.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/27/2023 12:56:17 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema
  xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric"
  xmlns:num="http://www.xbrl.org/dtr/type/numeric"
  xmlns:us-types="http://fasb.org/us-types/2022"
  xmlns:glue="http://monterosatx.com/20231026"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:xbrli="http://www.xbrl.org/2003/instance"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
  attributeFormDefault="unqualified"
  elementFormDefault="qualified"
  targetNamespace="http://monterosatx.com/20231026"
  xmlns:xsd="http://www.w3.org/2001/XMLSchema">
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
    <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" namespace="http://xbrl.sec.gov/dei/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
    <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
    <xsd:import schemaLocation="https://xbrl.sec.gov/naics/2022/naics-2022.xsd" namespace="http://xbrl.sec.gov/naics/2022" />
    <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="glue-20231026_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="glue-20231026_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>glue-20231026_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/27/2023 12:56:17 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
  xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CoverAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cover [Abstract]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation State Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityFileNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_CityAreaCode_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_LocalPhoneNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Written Communications</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_WrittenCommunications_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written Communications</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Soliciting Material</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SolicitingMaterial_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Soliciting Material</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pre Commencement Issuer Tender Offer</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre Commencement Issuer Tender Offer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security 12b Title</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_Security12bTitle_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security 12b Title</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_SecurityExchangeName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" />
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>glue-20231026_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFIN - https://www.dfinsolutions.com/ -->
<!-- CTU Version: Release master Build:20221108.6 -->
<!-- Creation date: 10/27/2023 12:56:17 AM Eastern Time -->
<!-- Copyright (c) 2023 Donnelley Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase
    xmlns:link="http://www.xbrl.org/2003/linkbase"
    xmlns:xlink="http://www.w3.org/1999/xlink"
    xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"
    xmlns:xbrldt="http://xbrl.org/2005/xbrldt"
    xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="glue-20231026.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <link:presentationLink xlink:type="extended" xlink:role="http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:type="locator" xlink:label="dei_CoverAbstract" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="22.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="23.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="25.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="26.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="27.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:type="locator" xlink:label="dei_EntityIncorporationStateCountryCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="28.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:type="locator" xlink:label="dei_EntityFileNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="29.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:type="locator" xlink:label="dei_EntityTaxIdentificationNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="30.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine1" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="31.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine2" xlink:type="locator" xlink:label="dei_EntityAddressAddressLine2" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="32.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:type="locator" xlink:label="dei_EntityAddressCityOrTown" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="33.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:type="locator" xlink:label="dei_EntityAddressStateOrProvince" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="34.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:type="locator" xlink:label="dei_EntityAddressPostalZipCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="35.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:type="locator" xlink:label="dei_CityAreaCode" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="36.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:type="locator" xlink:label="dei_LocalPhoneNumber" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="37.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_WrittenCommunications" xlink:type="locator" xlink:label="dei_WrittenCommunications" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_WrittenCommunications" order="38.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SolicitingMaterial" xlink:type="locator" xlink:label="dei_SolicitingMaterial" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SolicitingMaterial" order="39.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementTenderOffer" order="40.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_PreCommencementIssuerTenderOffer" xlink:type="locator" xlink:label="dei_PreCommencementIssuerTenderOffer" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_PreCommencementIssuerTenderOffer" order="41.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:type="locator" xlink:label="dei_Security12bTitle" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="42.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="43.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:type="locator" xlink:label="dei_SecurityExchangeName" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="44.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:type="locator" xlink:label="dei_EntityEmergingGrowthCompany" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="45.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:type="locator" xlink:label="dei_EntityExTransitionPeriod" />
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="46.001" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>g512767g1026185919418.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g512767g1026185919418.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  ] -\# 2(  A$! Q$!_\0
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M:$GJO\2?AU'XUXU7"S=+V\MWJ_0]>EB8JK[%;+1'K-8OB_GP9K>?^?&;_P!
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M0"!KF>6Z@.&$:D[02QYQG J_XX_Y&/P5_P!A8_\ HMJV_%X_XHS7.W^@3?\
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M1E5U*LH92,$$<$4M% $5M;0VEO';V\210QC:D:+A5'H!4M%% !1110 4444
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MDFM0.#U?64O=%T=_&'AV.+2K[>UR\FYC8OG]T7P,KD=6XP>*Y_6+BST<6_\
MPKO7+J^U21\#38KIKN%H]I+,P8G;CC!R.>*]A*AE*L,@C!![U%!:6]MGR((H
,MW7RT"Y_*FIV __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>g512767g1026185941264.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g512767g1026185941264.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  L ,@# 2(  A$! Q$!_\0
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MK6(E8)8R< >@< @CT'!%,N+3Q1\4=4M1>Z?)I6B0/N.\$9]2,@%FQP#C _F
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.23.3</span><table class="report" border="0" cellspacing="2" id="idm140675655100704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th"><div>Oct. 26, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001826457<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Oct. 26,  2023<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">MONTE ROSA THERAPEUTICS, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation State Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-40522<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">84-3766197<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">321 Harrison Avenue<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">(617)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">949-2643<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre Commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre Commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Security 12b Title</a></td>
<td class="text">Common Stock, $0.0001 par value per share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">GLUE<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>d512767d8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="glue-20231026.xsd" xlink:type="simple"/>
    <context id="duration_2023-10-26_to_2023-10-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001826457</identifier>
        </entity>
        <period>
            <startDate>2023-10-26</startDate>
            <endDate>2023-10-26</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="duration_2023-10-26_to_2023-10-26">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="duration_2023-10-26_to_2023-10-26"
      id="Hidden_dei_EntityCentralIndexKey">0001826457</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="duration_2023-10-26_to_2023-10-26">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="duration_2023-10-26_to_2023-10-26">2023-10-26</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="duration_2023-10-26_to_2023-10-26">MONTE ROSA THERAPEUTICS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="duration_2023-10-26_to_2023-10-26">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="duration_2023-10-26_to_2023-10-26">001-40522</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="duration_2023-10-26_to_2023-10-26">84-3766197</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="duration_2023-10-26_to_2023-10-26">321 Harrison Avenue</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="duration_2023-10-26_to_2023-10-26">Suite 900</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="duration_2023-10-26_to_2023-10-26">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="duration_2023-10-26_to_2023-10-26">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="duration_2023-10-26_to_2023-10-26">02118</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="duration_2023-10-26_to_2023-10-26">(617)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="duration_2023-10-26_to_2023-10-26">949-2643</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="duration_2023-10-26_to_2023-10-26">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="duration_2023-10-26_to_2023-10-26">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="duration_2023-10-26_to_2023-10-26">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="duration_2023-10-26_to_2023-10-26">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="duration_2023-10-26_to_2023-10-26">Common Stock, $0.0001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="duration_2023-10-26_to_2023-10-26">GLUE</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="duration_2023-10-26_to_2023-10-26">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="duration_2023-10-26_to_2023-10-26">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="duration_2023-10-26_to_2023-10-26">false</dei:EntityExTransitionPeriod>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>13
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MSK\>Y VCXNR-?:D,O/]GAQO!87G:&^#Z2BGSV; ? 8IO.,-_ 5!+ P04
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MJ'7N0;#W\!J-'<V/'[?\ 5!+ P04    "  =B%I7)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ '8A:5V60>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M"  =B%I7!T%-8H$   "Q    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( !V(6E?'*?0A[@   "L"   1
M  "  :\   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( !V(6E>97)PC
M$ 8  )PG   3              "  <P!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ '8A:5VPA-IB*!   SQ$  !@              ("!#0@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( !V(6E>?H!OP
ML0(  .(,   -              "  <T,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ '8A:5Y>*NQS     $P(   L              ( !J0\  %]R96QS
M+RYR96QS4$L! A0#%     @ '8A:5QPX9>H_ 0  / (   \
M ( !DA   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !V(6E<D'INBK0
M /@!   :              "  ?X1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( !V(6E=ED'F2&0$  ,\#   3              "
M >,2  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(  "T4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.23.3</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>24</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="d512767d8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="d512767d8k.htm">d512767d8k.htm</File>
    <File>glue-20231026.xsd</File>
    <File>glue-20231026_lab.xml</File>
    <File>glue-20231026_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="24">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>18
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "d512767d8k.htm": {
   "nsprefix": "glue",
   "nsuri": "http://monterosatx.com/20231026",
   "dts": {
    "inline": {
     "local": [
      "d512767d8k.htm"
     ]
    },
    "schema": {
     "local": [
      "glue-20231026.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd",
      "https://xbrl.sec.gov/naics/2022/naics-2022.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "glue-20231026_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "glue-20231026_pre.xml"
     ]
    }
   },
   "keyStandard": 24,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2022": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 25,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2022": 24
   },
   "report": {
    "R1": {
     "role": "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation",
     "longName": "100000 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "duration_2023-10-26_to_2023-10-26",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d512767d8k.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "duration_2023-10-26_to_2023-10-26",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "d512767d8k.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CityAreaCode",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "City Area Code",
        "terseLabel": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Issuer Tender Offer",
        "terseLabel": "Pre Commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "terseLabel": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Incorporation State Country Code",
        "terseLabel": "Entity Incorporation State Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Written Communications",
        "terseLabel": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "Security12bTitle",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Security 12b Title",
        "terseLabel": "Security 12b Title",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "DocumentType",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "terseLabel": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Soliciting Material",
        "terseLabel": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Pre Commencement Tender Offer",
        "terseLabel": "Pre Commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityExTransitionPeriod": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityExTransitionPeriod",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period",
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity File Number",
        "terseLabel": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "TradingSymbol",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://monterosatx.com//20231026/taxonomy/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Section": "14a",
   "Number": "240",
   "Subsection": "12"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "7A",
   "Section": "B",
   "Subsection": "2"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>19
<FILENAME>0001193125-23-264162-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-23-264162-xbrl.zip
M4$L#!!0    ( !V(6E>:,CE27!(  -5U   .    9#4Q,C<V-V0X:RYH=&WM
M'6MSXD;R>ZKR'Z;8)(6K#$@"/\!>7SF8W7#QVB[P5E+W)35( ^A6:!3-R(;[
M]=<](PD!XF5CO+OQ5B5&S*NGW]W3(\[_-1YYY(&%PN7^^X)9-@J$^39W7'_P
MOA#)?NFT0/YU\>,/YT,)':&S+QH.<]\7AE(&C4IEW N]LF!V>< ?*M!0L0S+
M*L0=(U&2DX")M'>?BEZ9AX-*TC+3W>>^'XW2SH^/CV4U/0YP9%C!$17H5()>
M+'3M9-S8<_TO,\,>JVJ06:_7*ZHUZ;K0,UW ,HQJ!9M[5+"D^\"+6-I]Q'W)
M0BZH')=M/D+0JZ9A':=@"#</")C8K/SYZ;IK#]F(EEQ?2.K;Z1*1#)<"5*]
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M^=EZZ3JRW?#[!H5DF.R/B\GB#XZF0?*T2=G7DHHSW5BO[KGL:^.2K41R<J[
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MSC3,C5AR0HWSBOY-2?6+DQ?_!U!+ P04    "  =B%I7D^!EN'):  "/I $
M$0   &0U,3(W-C=D97@Q,#$N:'1M[;U[<]O(DB_XOR+T'1">F1M2!*R6_.AN
MVWT<5[;5W=[Q:RSUZ7MV8_\ 25#",0CP *!DSJ???%9E%4!2LMRB)]83<^>V
M1:!0CZQ\YR]_^?WL[9OGO_Q^<OSJ^>[.+V>OS]Z</#_Y/_>/#@^.?OF!_PE_
M_T$>2'YY\?[5/Y(7O[U\_^;]Q[_=^_/WUV<G]Y+3LW^\.?G;O;*H\OL7>7%^
MT3U]5S>SK+SW/-G=@?=?YE67-\]_>?7Z[_KP53'I+I[^?/"XJ.XE65F<5S!
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MB-Q-77S!.WSTD (R0)\.NFBJ>@9LD<SN;#RNFTE6C7..?N'/,L]E0,_[::#
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M1?YXS.C^KXBZR!\>Q>D&UN,1N N/'J)7',[DZ/'>9)_-670>JF6%V<A+S/H
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M('E!G%9^LD?0E^_*,SUD+6X6_62F7RZYJD17EDDC12[R4G#3T RD,_Y"S7^
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MAX6IB[7#!'R%7.=W<GKRT;_WJ:0N,N4295<>MXD5X3;L[D2>T8[1O"BN-E2
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MGJ0*$$0,[PG1HN\Y5V9S8=_4@PC;"&()!&4.N(96,MQ^(J8MUJE(U8. NI$
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MA*C:ID^5;U[5-0O0I? =;A 3]*URS:K2GLZC0#+:VDI\#A,'Y&(3I!&=E"X
M0KU@ 4\V@_<0%4\<%)JXC)4W%5<$N633?N,0[*3HN"AA&8I=3Q6%K+PA(HP
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M3^.RF*Z>8Z@T8U8:^J$=\R''UA#W\3A;")^!D' Y-1!PYY:RGN^=QRR$&&>
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MJ/_1&NXDD$<V8A GR7B_JB0WS:2B+;#P3>R0_4J^/:G-N;PT&5/<//S7 (/
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MI=4)0!O5IVN:%614-O4(TN(30,OB='(?PMBDY=I)8A+42ZH3KOT2=!& T*!
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M A-$R^H,*"5LJ=D 16P$VEBQ8D4U0;G1UL/QXY_ GX&)P.J6;)>UC/#XL<B
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MUHZ^O;#Q7*Y*'F4W?F:'X_H>VC&!J(\D7 60,J?8\T(R(IE8:!9@N+.H=,U
MJJ"<+Q(:,YJ7K\;'*%I8\B=*'\*7C&\8OD!K2[@$Z22#'4X(PY>)Y14QXOHR
MD>$GCAS4)EO9;!541+='B(R4UU'H,S''7<EJ*@+J11I78D/;\[7[#DF$(&6G
M.!DS! 1+C>:\%>51+TV/WHS,RL"9HMA-T7X+3%M=L'#-T7N.=L2E[$A2TX8A
M?HXJ;"VD/)4C,NAKLE.$'PE<"2JPXLQFIY.J_9O+3;?<D##L%A4N6VY(KX=R
MB&8>(/.T'G!B?R7XQ9;@S C@Q-@U&U79?6SSJ0D6L_6#-@5*8T ?#G\#3&^"
M?VN,;=LNO.D2CYOD3ORXT5*5I,EN2$7Y<'5[RF)EPXE<H!2^IXN;BC$ *]FP
MP&D1?5!-<32B^+!S6%HFVJ]5%[6D2L@X:B=6]5+!?>WIMO5T3ZX7;=*41"!^
M)\_YR5!6'2P_$S[4T0B8R"[1 13HP.==DQ'/>\ J!L@N7&2;+C.Y'%5T#F5[
MH_"RL1+K2MUF:%Q+M(7'"W?A0]'&&;:6)6,\C$CP,#,%?TKKM4-Y-Y+6SXN
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M8=+D=F82U[J8 /O+-("7/TTE$83YYS-:)RJ\RMX_AU (&D4:QK=3IU!.4-2
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MDB(*7=A6QPW4%]+^'&EUS(!,Q/4VL\O1M3 )D$@Q\UGLFL(H03I!I21-5>0
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M:LD8N,, 096O.Y>.@3BZ5/X<WLMB\G#/*]5[B DR);>92V9S>>MP1HK'P)I
M P3<P$<.*R05#;?=,,"(T7)&[&YUQ.">K<YOBX":TMP!'-ELD#E\(A*_%</A
MQ5>V#=2+[QSZUN'9;U0?.91NG6:&"5Q&<7<WC#1!\#)'7"@#4,IQI++G)%&
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M3$>>Z14*S=H.;M<R]<-[.=GX8D0PN389>&_U+;:A:ZC QAE^S1R+5XIQ\7'
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M!S8" '$?#F!$,[6"*GM&;35=C]$%&/HD9*34V/4!R<:A1[_7^75UA^$]>ZF
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MP+^^,#S:,#N"3BY/_\ B?V?O_U!+ P04    "  =B%I7MW6<\$,#  !+"P
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M2P$"% ,4    "  =B%I7FC(Y4EP2  #5=0  #@              @ $
M9#4Q,C<V-V0X:RYH=&U02P$"% ,4    "  =B%I7D^!EN'):  "/I $ $0
M            @ &($@  9#4Q,C<V-V1E>#$P,2YH=&U02P$"% ,4    "  =
MB%I7"FI$T21!  "3' $ $               @ $I;0  9#4Q,C<V-V1E>#0Q
M+FAT;5!+ 0(4 Q0    ( !V(6E>VZ%H:.1$  (8Y   0              "
M 7NN  !D-3$R-S8W9&5X-3$N:'1M4$L! A0#%     @ '8A:5^=S @NL#0
MNB<  !$              ( !XK\  &0U,3(W-C=D97@Y.3$N:'1M4$L! A0#
M%     @ '8A:5[=UG/!# P  2PL  !$              ( !O<T  &=L=64M
M,C R,S$P,C8N>'-D4$L! A0#%     @ '8A:5YL\1AVL!@  IDD  !4
M         ( !+]$  &=L=64M,C R,S$P,C9?;&%B+GAM;%!+ 0(4 Q0    (
M !V(6E?$0?F%X 0  /\M   5              "  0[8  !G;'5E+3(P,C,Q
A,#(V7W!R92YX;6Q02P4&      @ " #[ 0  (=T

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
